Hashimoto Takayuki
| Faculty of Medicine Global Center for BiomedicalScience and Engineering | Professor |
| Hokkaido University Hospital | Professor |
Last Updated :2025/06/07
■Researcher basic information
Researchmap personal page
J-Global ID
Educational Organization
- Bachelor's degree program, Departments of Medicine, School of Medicine
- Master's degree program, Graduate School of Biomedical Science and Engineering
- Doctoral (PhD) degree program, Graduate School of Biomedical Science and Engineering
■Research activity information
Papers
- Long-term outcome and social-intellectual ability of patients with basal ganglia germinoma
Michinari Okamoto, Shigeru Yamaguchi, Ryosuke Sawaya, Yukitomo Ishi, Hiroaki Motegi, Yukayo Terashita, Minako Sugiyama, Yuko Cho, Kentaro Nishioka, Takashi Mori, Takayuki Hashimoto, Hidefumi Aoyama, Atsushi Manabe, Miki Fujimura
Pediatric Neurology, Elsevier BV, Jan. 2025
Scientific journal - Cost-effectiveness analysis for multi adverse events of proton beam therapy for pediatric medulloblastoma in Japan
Takaaki Yoshimura, Yasuhiro Morii, Honoka Tamori, Ryuki Kita, Takayuki Hashimoto, Hidefumi Aoyama, Katsuhiko Ogasawara
Journal of Radiation Research, Oxford University Press (OUP), 19 Nov. 2024
Scientific journal, Abstract
Medulloblastomas are one of the most common malignant cancers of the central nervous system in children. Proton beam therapy (PBT) is expected to provide equivalent tumor control to photon therapy while reducing the various adverse events caused by irradiation. Few studies have considered the cost-effectiveness of PBT for pediatric medulloblastoma, considering the multiple adverse effects and reflecting on the latest treatment advancements. A cost-utility analysis of PBT for pediatric medulloblastoma was conducted in a Japanese setting and compared to conventional photon therapy. The analysis was conducted from the public healthcare payer’s perspective, and direct costs for the treatment of radiation therapy and radiation-induced adverse events were included. A Markov model was used, and the health states of secondary cancer, hypothyroidism and hearing loss were defined as adverse events. The time horizon was the lifetime. Incremental cost-effectiveness ratio (ICER) was used as a measurement of cost-effectiveness, with quality-adjusted life years (QALYs) used as an outcome. The costs were estimated from the national fee schedule, and the utility and transition probabilities were estimated from published literature. PBT incurred an additional 1387116 Japanese yen (JPY) and 1.56 QALYs to the comparator. The ICER was JPY 887053/QALY, indicating that PBT was cost-effective, based on the reference value of JPY 5 million/QALY used in the Japanese cost-effectiveness analysis. Deterministic sensitivity analysis showed that the ICER ranged from JPY 284782/QALY to JPY 1918603/QALY as a result of deterministic sensitivity analysis, and probabilistic sensitivity analysis showed that PBT was cost-effective, with a probability of 91.7%. - Decision regret after curative treatment and its association with the decision-making process and quality of life for prostate cancer patients.
Miho Sato, Takahiro Osawa, Kentaro Nishioka, Tomohiko Miyazaki, Shuhei Takahashi, Takashi Mori, Takayuki Hashimoto, Haruka Miyata, Ryuji Matsumoto, Takashige Abe, Kazuki Ohashi, Sachiyo Murai, Yoichi M Ito, Nobuo Shinohara
International journal of urology : official journal of the Japanese Urological Association, 09 Oct. 2024, [International Magazine]
English, Scientific journal, OBJECTIVES: To determine how the treatment decision-making process and posttreatment health-related quality of life (HRQOL) are related to regret about treatment choice for prostate cancer patients in Japan. METHODS: We invited a total of 614 patients who were treated with radiation therapy (RT), radical prostatectomy (RP), or active surveillance/watchful waiting (AS/WW) from April 2007 to March 2021. Posttreatment regret was evaluated by the Decision Regret Scale. HRQOL was evaluated by the Expanded Prostate Cancer Index Composite and the 12-item Short Form Survey. The decision-making process was assessed by patient evaluation of the decision-making process. We compared the decision regret scale scores across treatment types, HRQOL, and decision-making processes. RESULTS: Data from 371 patients were analyzed (RT: 202, RP: 149, AS/WW: 20). The median length of time since treatment was 64 (IQR: 43-93) months. The decision regret scale scores were not significantly different among the treatment groups but were significantly greater (strong regret) in patients with poor urinary summary scores, bowel summary scores, and hormonal summary scores. The decision regret scale scores were significantly lower (less regret) for patients who reported being adequately informed at the time of the treatment decision and who had adequately communicated their questions and concerns to physicians than for patients who reported less adequate communication. This result was also observed among patients who reported low HRQOL scores. CONCLUSIONS: These findings underline the important influence of posttreatment HRQOL and decision-making as an interactive process between physicians and their patients on posttreatment regret in prostate cancer patients. - A simulation study of MR-guided proton therapy system using iron-yoked superconducting open MRI: a conceptual study.
Yusuke Fujii, Hideaki Ueda, Taisuke Takayanagi, Kentaro Nishioka, Takashi Mori, Takayuki Hashimoto, Hidefumi Aoyama, Kikuo Umegaki, Taeko Matsuura
Journal of radiation research, 04 Oct. 2024, [International Magazine]
English, Scientific journal, Radiotherapy platforms integrated with magnetic resonance imaging (MRI) have been significantly successful and widely used in X-ray therapy over the previous decade. MRI provides greater soft-tissue contrast than conventional X-ray techniques, which enables more precise radiotherapy with on-couch adaptive treatment planning and direct tracking of moving tumors. The integration of MRI into a proton beam irradiation system (PBS) is still in the research stage. However, this could be beneficial as proton therapy is more sensitive to anatomical changes and organ motion. In this simulation study, we considered the integration of PBS into the 0.3-T superconducting open MRI system. Our proposed design involves proton beams traversing a hole at the center of the iron yoke, which allows for a reduced fringe field in the irradiation nozzle while maintaining a large proton scan field of the current PBS. The shape of the bipolar MRI magnets was derived to achieve a large MRI field-of-view. To monitor the beam position and size accurately while maintaining a small beam size, the beam monitor installation was redesigned from the current system. The feasibility of this system was then demonstrated by the treatment plan quality, which showed that the magnetic field did not deteriorate the plan quality from that without the magnetic field for both a rectangular target and a prostate case. Although numerous challenges remain before the proposed simulation model can be implemented in a clinical setting, the presented conceptual design could assist in the initial design for the realization of the MR-guided proton therapy. - 前立腺がん患者における治療決定時の意思決定プロセスと治療後の後悔との関連
佐藤 三穂, 大澤 崇宏, 宮田 遥, 松本 隆児, 安部 崇重, 西岡 健太郎, 宮崎 智彦, 高橋 周平, 森 崇, 橋本 孝之, 大橋 和貴, 村井 祥代, 伊藤 陽一, 篠原 信雄
日本癌治療学会学術集会抄録集, 62回, YOA O22, 5, (一社)日本癌治療学会, Oct. 2024
Japanese - Geometric target margin strategy of proton craniospinal irradiation for pediatric medulloblastoma.
Takaaki Yoshimura, Keigo Kondo, Takayuki Hashimoto, Kentaro Nishioka, Takashi Mori, Takahiro Kanehira, Taeko Matsuura, Seishin Takao, Hiroshi Tamura, Takuya Matsumoto, Kenneth Sutherland, Hidefumi Aoyama
Journal of radiation research, 15 Sep. 2024, [International Magazine]
English, Scientific journal, In proton craniospinal irradiation (CSI) for skeletally immature pediatric patients, a treatment plan should be developed to ensure that the dose is uniformly delivered to all vertebrae, considering the effects on bone growth balance. The technical (t) clinical target volume (CTV) is conventionally set by manually expanding the CTV from the entire intracranial space and thecal sac, based on the physician's experience. However, there are differences in contouring methods among physicians. Therefore, we aimed to propose a new geometric target margin strategy. Nine pediatric patients with medulloblastoma who underwent proton CSI were enrolled. We measured the following water equivalent lengths for each vertebra in each patient: body surface to the dorsal spinal canal, vertebral limbus, ventral spinal canal and spinous processes. A simulated tCTV (stCTV) was created by assigning geometric margins to the spinal canal using the measurement results such that the vertebral limb and dose distribution coincided with a margin assigned to account for the uncertainty of the proton beam range. The stCTV with a growth factor (correlation between body surface area and age) and tCTV were compared and evaluated. The median values of each index for cervical, thoracic and lumber spine were: the Hausdorff distance, 9.14, 9.84 and 9.77 mm; mean distance-to-agreement, 3.26, 2.65 and 2.64 mm; Dice coefficient, 0.84, 0.81 and 0.82 and Jaccard coefficient, 0.50, 0.60 and 0.62, respectively. The geometric target margin setting method used in this study was useful for creating an stCTV to ensure consistent and uniform planning. - 当院における仙骨脊索腫に対する陽子線治療の後方視的検討
檜垣 朔, 田口 大志, 宮崎 智彦, 森 崇, 西岡 健太郎, 加藤 徳雄, 橋本 孝之, 田村 昌也, 高尾 聖心, 松浦 妙子, 青山 英史
日本医学放射線学会秋季臨床大会抄録集, 60回, S442, S442, (公社)日本医学放射線学会, Sep. 2024
Japanese - EVALUATION OF THE ACTUAL DOSE DISTRIBUTION USING CBCT FOR ULTRA-HYPOFRACTIONATED INTENSITY MODULATED PROTON THERAPY IN PROSTATE CANCER
Hiroshi Tamura, Keiji Nakazato, Takaaki Yoshimura, Hiroto Yoshimoto, Yuto Matsuo, Keiichi Magota, Seishin Takao, Taeko Matsuura, Takashi Mori, Kentaro Nishioka, Takayuki Hashimoto, Hidefumi Aoyama
International Journal of Particle Therapy, 12, 100456, 100456, Elsevier BV, Jun. 2024
Scientific journal - A Single-Institution Prospective Study To Evaluate the Safety and Efficacy of Real- Time Image-Gated Spot-Scanning Proton Therapy (RGPT) for Prostate Cancer.
Kentaro Nishioka, Takayuki Hashimoto, Takashi Mori, Yusuke Uchinami, Rumiko Kinoshita, Norio Katoh, Hiroshi Taguchi, Koichi Yasuda, Yoichi M Ito, Seishin Takao, Masaya Tamura, Taeko Matsuura, Shinichi Shimizu, Hiroki Shirato, Hidefumi Aoyama
Advances in radiation oncology, 9, 5, 101464, 101464, May 2024, [International Magazine]
English, Scientific journal, PURPOSE: In real-time image-gated spot-scanning proton therapy (RGPT), the dose distribution is distorted by gold fiducial markers placed in the prostate. Distortion can be suppressed by using small markers and more than 2 fields, but additional fields may increase the dose to organs at risk. Therefore, we conducted a prospective study to evaluate the safety and short-term clinical outcome of RGPT for prostate cancer. METHODS AND MATERIALS: Based on the previously reported frequency of early adverse events (AE) and the noninferiority margin of 10%, the required number of cases was calculated to be 43 using the one-sample binomial test by the Southwest Oncology Group statistical tools with the one-sided significance level of 2.5% and the power 80%. Patients with localized prostate cancer were enrolled and 3 to 4 pure gold fiducial markers of 1.5-mm diameter were inserted in the prostate. The prescribed dose was 70 Gy(relative biologic effectiveness) in 30 fractions, and treatment was performed with 3 fields from the left, right, and the back, or 4 fields from either side of slightly anterior and posterior oblique fields. The primary endpoint was the frequency of early AE (≥grade 2) and the secondary endpoint was the biochemical relapse-free survival rate and the frequency of late AE. RESULTS: Forty-five cases were enrolled between 2015 and 2017, and all patients completed the treatment protocol. The median follow-up period was 63.0 months. The frequency of early AE (≥grade 2) was observed in 4 cases (8.9%), therefore the noninferiority was verified. The overall 5-year biochemical relapse-free survival rate was 88.9%. As late AE, grade 2 rectal bleeding was observed in 8 cases (17.8%). CONCLUSIONS: The RGPT for prostate cancer with 1.5-mm markers and 3- or 4- fields was as safe as conventional proton therapy in early AE, and its efficacy was comparable with previous studies. - A new predictive parameter for dose‐volume metrics in intensity‐modulated radiation therapy planning for prostate cancer: Initial phantom study
Yuki Saito, Ryusuke Suzuki, Naoki Miyamoto, Kenneth Lee Sutherland, Takahiro Kanehira, Masaya Tamura, Takashi Mori, Kentaro Nishioka, Takayuki Hashimoto, Hidefumi Aoyama
Journal of Applied Clinical Medical Physics, Apr. 2024, [Peer-reviewed]
Scientific journal - Probability of normal tissue complications for hematologic and gastrointestinal toxicity in postoperative whole pelvic radiotherapy for gynecologic malignancies using intensity-modulated proton therapy with robust optimization.
Takaaki Yoshimura, Ryota Yamada, Rumiko Kinoshita, Taeko Matsuura, Takahiro Kanehira, Hiroshi Tamura, Kentaro Nishioka, Koichi Yasuda, Hiroshi Taguchi, Norio Katoh, Keiji Kobashi, Takayuki Hashimoto, Hidefumi Aoyama
Journal of radiation research, 17 Mar. 2024, [International Magazine]
English, Scientific journal, This retrospective treatment-planning study was conducted to determine whether intensity-modulated proton therapy with robust optimization (ro-IMPT) reduces the risk of acute hematologic toxicity (H-T) and acute and late gastrointestinal toxicity (GI-T) in postoperative whole pelvic radiotherapy for gynecologic malignancies when compared with three-dimensional conformal radiation therapy (3D-CRT), intensity-modulated X-ray (IMXT) and single-field optimization proton beam (SFO-PBT) therapies. All plans were created for 13 gynecologic-malignancy patients. The prescribed dose was 45 GyE in 25 fractions for 95% planning target volume in 3D-CRT, IMXT and SFO-PBT plans and for 99% clinical target volume (CTV) in ro-IMPT plans. The normal tissue complication probability (NTCP) of each toxicity was used as an in silico surrogate marker. Median estimated NTCP values for acute H-T and acute and late GI-T were 0.20, 0.94 and 0.58 × 10-1 in 3D-CRT; 0.19, 0.65 and 0.24 × 10-1 in IMXT; 0.04, 0.74 and 0.19 × 10-1 in SFO-PBT; and 0.06, 0.66 and 0.15 × 10-1 in ro-IMPT, respectively. Compared with 3D-CRT and IMXT plans, the ro-IMPT plan demonstrated significant reduction in acute H-T and late GI-T. The risk of acute GI-T in ro-IMPT plan is equivalent with IMXT plan. The ro-IMPT plan demonstrated potential clinical benefits for reducing the risk of acute H-T and late GI-T in the treatment of gynecologic malignances by reducing the dose to the bone marrow and bowel bag while maintaining adequate dose coverage to the CTV. Our results indicated that ro-IMPT may reduce acute H-T and late GI-T risk with potentially improving outcomes for postoperative gynecologic-malignancy patients with concurrent chemotherapy. - 北大病院放射線治療科関連施設における乳癌の放射線治療に関するアンケート結果リンパ節領域に対する照射について
木下 留美子, 田口 大志, 高橋 周平, 宮崎 智彦, 森 崇, 西岡 健太郎, 橋本 孝之, 青山 英史
北海道外科雑誌, 68, 2, 163, 164, 北海道外科学会, Dec. 2023
Japanese - 【臨床脳腫瘍学-最新の診断・治療と病態-】脳腫瘍の治療 脳腫瘍の放射線療法・他 放射線療法 概論
青山 英史, 西岡 健太郎, 橋本 孝之
日本臨床, 81, 増刊9 臨床脳腫瘍学, 362, 366, (株)日本臨床社, Dec. 2023
Japanese - Slow-growing WNT medulloblastoma with atypical magnetic resonance imaging findings: illustrative case.
Makoto Mizushima, Michinari Okamoto, Shigeru Yamaguchi, Sogo Oki, Hiroaki Motegi, Minako Sugiyama, Atsushi Manabe, Ai Shimizu, Kentaro Nishioka, Takayuki Hashimoto, Junko Hirato, Yonehiro Kanemura, Miki Fujimura
Journal of neurosurgery. Case lessons, 6, 7, 14 Aug. 2023, [International Magazine]
English, Scientific journal, BACKGROUND: Medulloblastomas, with four molecular subgroups, are generally rapid-growing tumors with significant contrast enhancement and well-defined margins. However, each subgroup's clinical features, including disease time course and imaging characteristics, are not well defined. OBSERVATIONS: The authors describe the case of a 15-year-old female who presented with a 7-month history of impaired left-hand movement and was found to have a lesion on the dorsal side of the fourth ventricle. T2-weighted magnetic resonance imaging (MRI) at the patient's first presentation showed diffuse hyperintense signal without apparent mass, and gadolinium-enhanced T1-weighted imaging showed very slight contrast enhancement. In 1 month, her symptoms progressed, and follow-up MRI revealed an increase in the size of the lesion, showing greater diffusion restriction and contrast enhancement. She underwent gross-total resection, and pathology was consistent with classic medulloblastoma. Genetic analysis of the tumor confirmed the wingless (WNT) molecular subgroup. Adjuvant chemotherapy and proton beam therapy were performed. At the 18-month follow-up, MRI showed no recurrence of disease. LESSONS: Slow-growing medulloblastoma is very rare and not known to be associated with a specific molecular subgroup. Here, the authors report a case of slow-growing WNT medulloblastoma, indicating that slow growth may be a feature of this subgroup. - PO-2122 Effect of early fractional lymphocyte loss on lymphopenia probability models for NSCLC
T. Kanehira, H. Taguchi, N. Katoh, Y. Uchinami, T. Yoshimura, M. Tamura, R. Suzuki, T. Hashimoto, H. Aoyama
Radiotherapy and Oncology, 182, S1909, S1911, Elsevier BV, May 2023
Scientific journal - Brain metastases in Japanese NSCLC patients: prognostic assessment and the use of osimertinib and immune checkpoint inhibitors-retrospective study.
Hajime Higaki, Kentaro Nishioka, Manami Otsuka, Noboru Nishikawa, Motoyasu Shido, Hideki Minatogawa, Yukiko Nishikawa, Rikiya Takashina, Takayuki Hashimoto, Norio Katoh, Hiroshi Taguchi, Rumiko Kinoshita, Koichi Yasuda, Takashi Mori, Yusuke Uchinami, Fuki Koizumi, Yoshihiro Fujita, Shuhei Takahashi, Takahiro Hattori, Noriaki Nishiyama, Hidefumi Aoyama
Radiation oncology (London, England), 18, 1, 25, 25, 07 Feb. 2023, [International Magazine]
English, Scientific journal, BACKGROUND: The Graded Prognostic Assessment for lung cancer using molecular markers (Lung-molGPA) has not been validated for use with Japanese non-small cell lung cancer (NSCLC) patients with brain metastasis (BM) and the factors impacting survival need to be assessed. METHODS: We retrospectively analyzed 294 NSCLC patients who were newly diagnosed with BM between 2013 and 2020 and had received radiotherapy for BM initially at the Hokkaido Cancer Center. We evaluated the effect on the prognosis of Lung-molGPA items, the expression of PD-L1 (classified as high, low, and no expression), and the treatment history. The main outcome was the survival measured from the day of the diagnosis of BM, and log-rank tests were performed to evaluate the results. RESULTS: The median overall survival (OS) times for adenocarcinoma by groups of GPA scores (0‒1.0, 1.5‒2.0, 2.5‒3.0, and 3.5‒4.0) were 5.5, 14.8, 28.3, and 39.0 months (p < 0.0001), respectively. The median survival times for non-adenocarcinoma by groups of GPA scores (0‒1.0, 1.5‒2.0, and 2.5‒3.0) were 3.2, 11.0, and 16.0 months (p = 0.0011), respectively. In adenocarcinoma patients with gene mutations, osimertinib significantly improved the outcome (median OS: 34.2 and 17.6 months with and without osimertinib, respectively (p = 0.0164)). There was no significant difference in the OS between patients who were initially treated with tyrosine-kinase inhibitor for BM and those who initially received radiotherapy (p = 0.5337). In patients tested for PD-L1 expression, the median survival times after the diagnosis of BM were 5.6, 22.5, and 9.3 months for the high-, low- and no-expression groups (p = 0.2198), respectively. Also, in patients with high PD-L1 expressions, those with ICI had survival (median OS, 8.6 months) than those without (median OS, 3.6 months). CONCLUSIONS: We confirmed that Lung-molGPA successfully classified Japanese NSCLC patients with BM by the prognosis. Osimertinib prolonged survival of EGFR-positive NSCLC patients with BM, and ICI was effective in patients with high PD-L1 expressions. - 尿管癌への放射線治療後に転移による直腸狭窄を来した1例
服部 敬寛, 西岡 健太郎, 橋本 孝之, 大塚 愛美, 木下 留美子, 青山 英史, 安部 崇重, 大澤 崇宏, 松本 隆児, 菊地 央, 篠原 信雄, 高桑 恵美
Japanese Journal of Radiology, 41, Suppl., 4, 4, (公社)日本医学放射線学会, Feb. 2023
Japanese - Distribution of human papilloma virus genotypes and treatment outcomes in definitive radiotherapy for cervical cancer.
Rumiko Kinoshita, Takashi Mitamura, Fumi Kato, Takahiro Hattori, Hajime Higaki, Shuhei Takahashi, Yoshihiro Fujita, Manami Otsuka, Fuki Koizumi, Yusuke Uchinami, Takashi Mori, Kentaro Nishioka, Takayuki Hashimoto, Yoichi M Ito, Hidemichi Watari, Hidefumi Aoyama
Journal of radiation research, 64, 2, 463, 470, 03 Jan. 2023, [International Magazine]
English, Scientific journal, Most oncogenic human papilloma virus (HPV) genotypes stratify into two species, α-7 HPV and α-9 HPV. There are several studies that evaluate the relationship between HPV species and treatment outcomes and reports that HPV species is prognostic. The HPV genotyping was conducted using biopsy specimens which had been stored in these studies. We conducted the study using the HPV test performed by cytology specimens which is less invasive and more useful in clinical settings. This study enrolled 46 patients who received HPV genotyping before the definitive radiotherapy. The results of the HPV genotyping were classified into HPVα-7, HPVα-9 and negatives. Of the 46 patients, 10 were positive for HPVα-7, 21 positive for HPVα-9 and 15 were negative. The median follow-up period was 38 months (range 4-142). The HPVα-7, HPVα-9 and negative groups showed the 3-year overall survival (OS; 59.3%, 80.4% and 72.2% [P = 0.25]); local control (LC; 67.5%, 81% and 80% [P = 0.78]); pelvic control (PC) (50%, 81% and 72.7% [P = 0.032]); pelvic lymph node (PLN) control (78.7%, 95% and 92.3% [P = 0.012]); distant metastasis free (DMF) survival (50%, 75.4% and 42.8% [P = 0.098]); and progression free survival (PFS) rate of patients (30%, 66.7% and 38.9% [P = 0.085]), respectively. Patients with HPVα-7 showed statistically significant poorer PC than the HPVα-9 group, in multivariate analysis. This result is consistent with previous studies for HPV positive patients. The HPV negativity rate was higher in this study than in other studies and further work on this may be needed for clinical use. - Prostatic urinary tract visualization with super-resolution deep learning models.
Takaaki Yoshimura, Kentaro Nishioka, Takayuki Hashimoto, Takashi Mori, Shoki Kogame, Kazuya Seki, Hiroyuki Sugimori, Hiroko Yamashina, Yusuke Nomura, Fumi Kato, Kohsuke Kudo, Shinichi Shimizu, Hidefumi Aoyama
PloS one, 18, 1, e0280076, 2023, [International Magazine]
English, Scientific journal, In urethra-sparing radiation therapy, prostatic urinary tract visualization is important in decreasing the urinary side effect. A methodology has been developed to visualize the prostatic urinary tract using post-urination magnetic resonance imaging (PU-MRI) without a urethral catheter. This study investigated whether the combination of PU-MRI and super-resolution (SR) deep learning models improves the visibility of the prostatic urinary tract. We enrolled 30 patients who had previously undergone real-time-image-gated spot scanning proton therapy by insertion of fiducial markers. PU-MRI was performed using a non-contrast high-resolution two-dimensional T2-weighted turbo spin-echo imaging sequence. Four different SR deep learning models were used: the enhanced deep SR network (EDSR), widely activated SR network (WDSR), SR generative adversarial network (SRGAN), and residual dense network (RDN). The complex wavelet structural similarity index measure (CW-SSIM) was used to quantitatively assess the performance of the proposed SR images compared to PU-MRI. Two radiation oncologists used a 1-to-5 scale to subjectively evaluate the visibility of the prostatic urinary tract. Cohen's weighted kappa (k) was used as a measure of agreement of inter-operator reliability. The mean CW-SSIM in EDSR, WDSR, SRGAN, and RDN was 99.86%, 99.89%, 99.30%, and 99.67%, respectively. The mean prostatic urinary tract visibility scores of the radiation oncologists were 3.70 and 3.53 for PU-MRI (k = 0.93), 3.67 and 2.70 for EDSR (k = 0.89), 3.70 and 2.73 for WDSR (k = 0.88), 3.67 and 2.73 for SRGAN (k = 0.88), and 4.37 and 3.73 for RDN (k = 0.93), respectively. The results suggest that SR images using RDN are similar to the original images, and the SR deep learning models subjectively improve the visibility of the prostatic urinary tract. - 強度変調回転照射法(VMAT)で術後照射を行った2例
木下 留美子, 檜垣 朔, 藤田 祥博, 森 崇, 西岡 健太郎, 橋本 孝之, 青山 英史, 押野 智博, 高橋 将人, 加藤 扶美, 金平 孝博
北海道外科雑誌, 67, 2, 162, 163, 北海道外科学会, Dec. 2022
Japanese - Long-term consequences of residual lesions after chemoradiotherapy in patients with germinoma at onset.
Shigeru Yamaguchi, Michinari Okamoto, Yukitomo Ishi, Ryosuke Sawaya, Hiroaki Motegi, Minako Sugiyama, Taisuke Harada, Noriyuki Fujima, Takashi Mori, Takayuki Hashimoto, Emi Takakuwa, Atsushi Manabe, Kohsuke Kudo, Hidefumi Aoyama, Miki Fujimura
Journal of neurosurgery. Pediatrics, 1, 8, 09 Sep. 2022, [International Magazine]
English, Scientific journal, OBJECTIVE: In patients with intracranial germ cell tumors, residual lesions are sometimes observed after completion of primary chemoradiotherapy. Although salvage resection of these end-of-treatment residual lesions is recommended for patients with nongerminomatous germ cell tumors, the necessity of early salvage resection for those with germinoma is not clear. The aim of this study was to investigate the frequency of residual germinoma lesions after primary chemoradiotherapy, as well as their management, long-term consequences, and prognosis. METHODS: The authors retrospectively reviewed patients who were primarily treated for germinoma between 2002 and 2021. Residual lesions were evaluated with MRI with and without contrast enhancement within 2 weeks after chemoradiotherapy. The decision to perform salvage resection of residual lesions was at the discretion of the treating physicians. The change in appearance of residual lesions was assessed with serial MRI. Overall survival (OS), progression-free survival (PFS), and recurrence pattern were also investigated. RESULTS: Sixty-nine patients were treated with chemoradiotherapy for germinoma, with a mean follow-up period of 108 months. Residual lesions were radiologically observed in 30 patients (43.5%). Among these, 5 patients (3 with pineal lesions and 2 with basal ganglia lesions) underwent salvage resection. Pathological examination revealed teratomatous components in 3 patients, whereas no tumoral components were identified in 2 patients. One patient with a basal ganglia lesion showed worsening of hemiparesis postoperatively. The remaining 25 patients received watchful observation without surgical intervention. Chronological periodic radiological change in residual lesions was evaluated in 21 patients. One year after primary treatment, the size of the residual lesions was stable and had decreased in 10 and 11 patients, respectively. None of the lesions increased in size. The 10-year PFS and OS rates were 96.7% and 97.3% in patients without residual lesions (n = 39), and 87.1% and 100% in patients with residual lesions (n = 30), respectively. Presence of residual lesions had no significant effect on PFS or OS. All recurrences occurred at distant sites or via dissemination without progression of the primary tumor site, regardless of the presence of residual lesion. CONCLUSIONS: End-of-treatment residual lesions are not rare in patients with germinoma, and these residual lesions seldom show progression. Because of the potential risk of surgical complications, the indication for early salvage surgery for residual lesions should be carefully determined. Watchful observation is recommended for the majority of these cases. - In reply to "Comment on "Particle therapy using protons or carbon ions for cancer patients with cardiac implantable electronic devices (CIED): a retrospective multi-institutional study"".
Takayuki Hashimoto
Japanese journal of radiology, 40, 5, 544, 545, May 2022, [Peer-reviewed], [Domestic magazines]
English - 北海道大学病院放射線治療科関連施設における子宮頸癌に対する根治放射線治療に関するアンケート結果について
木下 留美子, 打浪 雄介, 高橋 周平, 小泉 富基, 森 崇, 西岡 健太郎, 田口 大志, 橋本 孝之, 高邑 明夫, 西岡 井子, 北原 利博, 土屋 和彦, 井上 哲也, 有本 卓郎, 出倉 康裕, 米坂 祥朗, 鈴木 恵士郎, 川島 和之, 小野寺 俊輔, 喜多村 圭, 長谷川 雅一, 鬼丸 力也, 富田 雅義, 池田 潤, 西山 典明, 青山 英史
北海道放射線医学雑誌, 2, 13, 18, (NPO)メディカルイメージラボ, Mar. 2022
Japanese - Dosimetric advantages of daily adaptive strategy in IMPT for high-risk prostate cancer.
Hiroshi Tamura, Keiji Kobashi, Kentaro Nishioka, Takaaki Yoshimura, Takayuki Hashimoto, Shinichi Shimizu, Yoichi M Ito, Yoshikazu Maeda, Makoto Sasaki, Kazutaka Yamamoto, Hiroyasu Tamamura, Hidefumi Aoyama, Hiroki Shirato
Journal of applied clinical medical physics, 23, 4, e13531, 19 Jan. 2022, [International Magazine]
English, Scientific journal, PURPOSE: To evaluate the dosimetric advantages of daily adaptive radiotherapy (DART) in intensity-modulated proton therapy (IMPT) for high-risk prostate cancer by comparing estimated doses of the conventional non-adaptive radiotherapy (NART) that irradiates according to an original treatment plan through the entire treatment and the DART that uses an adaptive treatment plan generated by using daily CT images acquired before each treatment. METHODS: Twenty-three patients with prostate cancer were included. A treatment plan with 63 Gy (relative biological effectiveness (RBE)) in 21 fractions was generated using treatment planning computed tomography (CT) images assuming that all patients had high-risk prostate cancer for which the clinical target volume (CTV) needs to include prostate and the seminal vesicle (SV) in our treatment protocol. Twenty-one adaptive treatment plans for each patient (total 483 data sets) were generated using daily CT images, and dose distributions were calculated. Using a 3 mm set-up uncertainty in the robust optimization, the doses to the CTV, prostate, SV, rectum, and bladder were compared. RESULTS: Estimated accumulated doses of NART and DART in the 23 patients were 60.81 ± 3.47 Gy (RBE) and 63.24 ± 1.04 Gy (RBE) for CTV D99 (p < 0.01), 62.99 ± 1.28 Gy (RBE) and 63.43 ± 1.33 Gy (RBE) for the prostate D99 (p = 0.2529), and 59.07 ± 5.19 Gy (RBE) and 63.17 ± 1.04 Gy (RBE) for SV D99 (p < 0.001). No significant differences were observed between NART and DART in the estimated accumulated dose for the rectum and bladder. CONCLUSION: Compared with the NART, DART was shown to be a useful approach that can maintain the dose coverage to the target without increasing the dose to the organs at risk (OAR) using the 3 mm set-up uncertainty in the robust optimization in patients with high-risk prostate cancer. - Impact of a spatially dependent dose delivery time structure on the biological effectiveness of scanning proton therapy.
Koki Kasamatsu, Sodai Tanaka, Koichi Miyazaki, Seishin Takao, Naoki Miyamoto, Shusuke Hirayama, Kentaro Nishioka, Takayuki Hashimoto, Hidefumi Aoyama, Kikuo Umegaki, Taeko Matsuura
Medical physics, 49, 1, 702, 713, Jan. 2022, [International Magazine]
English, Scientific journal, PURPOSE: In the scanning beam delivery of protons, different portions of the target are irradiated with different linear energy transfer protons with various time intervals and irradiation times. This research aimed to evaluate the spatially dependent biological effectiveness of protracted irradiation in scanning proton therapy. METHODS: One and two parallel opposed fields plans were created in water phantom with the prescribed dose of 2 Gy. Three scenarios (instantaneous, continuous, and layered scans) were used with the corresponding beam delivery models. The biological dose (physical dose × relative biological effectiveness) was calculated using the linear quadratic model and the theory of dual radiation action to quantitatively evaluate the dose delivery time effect. In addition, simulations using clinical plans (postoperative seminoma and prostate tumor cases) were conducted to assess the impact of the effects on the dose volume histogram parameters and homogeneity coefficient (HC) in targets. RESULTS: In a single-field plan of water phantom, when the treatment time was 19 min, the layered-scan scenario showed a decrease of <0.2% (almost 3.3%) in the biological dose from the plan on the distal (proximal) side because of the high (low) dose rate. This is in contrast to the continuous scenario, where the biological dose was almost uniformly decreased over the target by approximately 3.3%. The simulation with clinical geometry showed that the decrease rates in D99% were 0.9% and 1.5% for every 10 min of treatment time prolongation for postoperative seminoma and prostate tumor cases, respectively, whereas the increase rates in HC were 0.7% and 0.2%. CONCLUSIONS: In protracted irradiation in scanning proton therapy, the spatially dependent dose delivery time structure in scanning beam delivery can be an important factor for accurate evaluation of biological effectiveness. - Particle therapy using protons or carbon ions for cancer patients with cardiac implantable electronic devices (CIED): a retrospective multi-institutional study.
Takayuki Hashimoto, Yusuke Demizu, Haruko Numajiri, Tomonori Isobe, Shigekazu Fukuda, Masaru Wakatsuki, Haruo Yamashita, Shigeyuki Murayama, Shigeyuki Takamatsu, Hiroyuki Katoh, Kazutoshi Murata, Ryosuke Kohno, Takeshi Arimura, Taeko Matsuura, Yoichi M Ito
Japanese journal of radiology, 40, 5, 525, 533, 15 Nov. 2021, [Peer-reviewed], [Domestic magazines]
English, Scientific journal, PURPOSE: To evaluate the outcomes of particle therapy in cancer patients with cardiac implantable electronic devices (CIEDs). MATERIALS AND METHODS: From April 2001 to March 2013, 19,585 patients were treated with proton beam therapy (PBT) or carbon ion therapy (CIT) at 8 institutions. Of these, 69 patients (0.4%, PBT 46, CIT 22, and PBT + CIT 1) with CIEDs (64 pacemakers, 4 implantable cardioverter defibrillators, and 1 with a cardiac resynchronization therapy defibrillator) were retrospectively reviewed. All the patients with CIEDs in this study were treated with the passive scattering type of particle beam therapy. RESULTS: Six (13%) of the 47 PBT patients, and none of the 23 CIT patients experienced CIED malfunctions (p = 0.105). Electrical resets (7) and over-sensing (3) occurred transiently in 6 patients. The distance between the edge of the irradiation field and the CIED was not associated with the incidence of malfunctions in 20 patients with lung cancer. A larger field size had a higher event rate but the test to evaluate trends as not statistically significant (p = 0.196). CONCLUSION: Differences in the frequency of occurrence of device malfunctions for patients treated with PBT and patients treated with CIT did not reach statistical significance. The present study can be regarded as a benchmark study about the incidence of malfunctioning of CIED in passive scattering particle beam therapy and can be used as a reference for active scanning particle beam therapy. - A treatment planning study of urethra-sparing intensity-modulated proton therapy for localized prostate cancer
Takaaki Yoshimura, Kentaro Nishioka, Takayuki Hashimoto, Kazuya Seki, Shouki Kogame, Sodai Tanaka, Takahiro Kanehira, Masaya Tamura, Seishin Takao, Taeko Matsuura, Keiji Kobashi, Fumi Kato, Hidefumi Aoyama, Shinichi Shimizu
Physics and Imaging in Radiation Oncology, 20, 23, 29, Elsevier BV, Oct. 2021, [International Magazine]
English, Scientific journal, BACKGROUND AND PURPOSE: Urethra-sparing radiation therapy for localized prostate cancer can reduce the risk of radiation-induced genitourinary toxicity by intentionally underdosing the periurethral transitional zone. We aimed to compare the clinical impact of a urethra-sparing intensity-modulated proton therapy (US-IMPT) plan with that of conventional clinical plans without urethral dose reduction. MATERIALS AND METHODS: This study included 13 patients who had undergone proton beam therapy. The prescribed dose was 63 GyE in 21 fractions for 99% of the clinical target volume. To compare the clinical impact of the US-IMPT plan with that of the conventional clinical plan, tumor control probability (TCP) and normal tissue complication probability (NTCP) were calculated with a generalized equivalent uniform dose-based Lyman-Kutcher model using dose volume histograms. The endpoints of these model parameters for the rectum, bladder, and urethra were fistula, contraction, and urethral stricture, respectively. RESULTS: The mean NTCP value for the urethra in US-IMPT was significantly lower than that in the conventional clinical plan (0.6% vs. 1.2%, p < 0.05). There were no statistically significant differences between the conventional and US-IMPT plans regarding the mean minimum dose for the urethra with a 3-mm margin, TCP value, and NTCP value for the rectum and bladder. Additionally, the target dose coverage of all plans in the robustness analysis was within the clinically acceptable range. CONCLUSIONS: Compared with the conventional clinically applied plans, US-IMPT plans have potential clinical advantages and may reduce the risk of genitourinary toxicities, while maintaining the same TCP and NTCP in the rectum and bladder. - Cost-effectiveness analysis using lifetime attributable risk of proton beam therapy for pediatric medulloblastoma in Japan.
Takaaki Yoshimura, Honoka Tamori, Yasuhiro Morii, Takayuki Hashimoto, Shinichi Shimizu, Katsuhiko Ogasawara
Journal of radiation research, 29 Sep. 2021, [International Magazine]
English, Scientific journal, Compared to conventional X-ray therapy, proton beam therapy (PBT) has more clinical and physical advantages such as irradiation dose reduction to normal tissues for pediatric medulloblastoma. However, PBT is expensive. We aimed to compare the cost-effectiveness of PBT for pediatric medulloblastoma with that of conventional X-ray therapy, while focusing on radiation-induced secondary cancers, which are rare, serious and negatively affect a patient's quality of life (QOL). Based on a systematic review, a decision tree model was used for the cost-effectiveness analysis. This analysis was performed from the perspective of health care payers; the cost was estimated from medical fees. The target population was pediatric patients with medulloblastoma below 14 years old. The time horizon was set at 7.7 years after medulloblastoma treatment. The primary outcome was the incremental cost-effectiveness ratio (ICER), which was defined as the ratio of the difference in cost and lifetime attributable risk (LAR) between conventional X-ray therapy and PBT. The discount rate was set at 2% annually. Sensitivity analyses were performed to model uncertainty. Cost and LAR in conventional X-ray therapy and PBT were Japanese yen (JPY) 1 067 608 and JPY 2436061 and 42% and 7%, respectively. The ICER was JPY 3856398/LAR. In conclusion, PBT is more cost-effective than conventional X-ray therapy in reducing the risk of radiation-induced secondary cancers in pediatric medulloblastoma. Thus, our constructed ICER using LAR is one of the valid indicators for cost-effectiveness analysis in radiation-induced secondary cancer. - 再照射 小児がんに対する陽子線再照射
橋本 孝之, 森 崇, 西岡 健太郎, 打浪 雄介, 安田 耕一, 木下 留美子, 田口 大志, 加藤 徳雄, 清水 伸一, 青山 英史
日本小児血液・がん学会雑誌, 58, 2, 89, 93, (一社)日本小児血液・がん学会, Aug. 2021
Japanese - Proton beam therapy for children and adolescents and young adults (AYAs): JASTRO and JSPHO Guidelines
Masashi Mizumoto, Hiroshi Fuji, Mitsuru Miyachi, Toshinori Soejima, Tetsuya Yamamoto, Norihiro Aibe, Yusuke Demizu, Hiromitsu Iwata, Takayuki Hashimoto, Atsushi Motegi, Atsufumi Kawamura, Keita Terashima, Takashi Fukushima, Tomohei Nakao, Akinori Takada, Minako Sumi, Junjiro Oshima, Kensuke Moriwaki, Miwako Nozaki, Yuji Ishida, Yoshiyuki Kosaka, Keisuke Ae, Ako Hosono, Hideyuki Harada, Etsuyo Ogo, Tetsuo Akimoto, Takashi Saito, Hiroko Fukushima, Ryoko Suzuki, Mitsuru Takahashi, Takayuki Matsuo, Akira Matsumura, Hidekazu Masaki, Hajime Hosoi, Naoyuki Shigematsu, Hideyuki Sakurai
Cancer Treatment Reviews, 98, 102209, 102209, Elsevier BV, Jul. 2021, [International Magazine]
English, Scientific journal, Children and adolescents and young adults (AYAs) with cancer are often treated with a multidisciplinary approach. This includes use of radiotherapy, which is important for local control, but may also cause adverse events in the long term, including second cancer. The risks for limited growth and development, endocrine dysfunction, reduced fertility and second cancer in children and AYAs are reduced by proton beam therapy (PBT), which has a dose distribution that decreases irradiation of normal organs while still targeting the tumor. To define the outcomes and characteristics of PBT in cancer treatment in pediatric and AYA patients, this document was developed by the Japanese Society for Radiation Oncology (JASTRO) and the Japanese Society of Pediatric Hematology/Oncology (JSPHO). - 泌尿器癌に対する局所療法-超高齢社会の先端医療のあり方は? 筋層浸潤性膀胱癌に対する集学的治療 化学放射線療法による膀胱温存について
安部 崇重, 宮田 遥, 山田 修平, 菊地 央, 松本 隆児, 大澤 崇宏, 西岡 健太郎, 橋本 孝之, 清水 伸一, 篠原 信雄
日本老年泌尿器科学会誌, 34, 1, 50, 50, 日本老年泌尿器科学会, Apr. 2021
Japanese - Visualizing the urethra by magnetic resonance imaging without usage of a catheter for radiotherapy of prostate cancer
Takaaki Yoshimura, Kentaro Nishioka, Takayuki Hashimoto, Taro Fujiwara, Kinya Ishizaka, Hiroyuki Sugimori, Shoki Kogame, Kazuya Seki, Hiroshi Tamura, Sodai Tanaka, Yuto Matsuo, Yasuhiro Dekura, Fumi Kato, Hidefumi Aoyama, Shinichi Shimizu
Physics and Imaging in Radiation Oncology, 18, 1, 4, Apr. 2021
Scientific journal - 尿量の経日変化および前立腺体積が放射線治療時の前立腺の位置に与える影響(The Impact of Daily Urinary Volume Variations and Prostate Volume on Prostate Position During Radiotherapy)
Nishioka Kentaro, Hashimoto Takayuki, Yokota Isao, Katoh Norio, Kinoshita Rumiko, Yasuda Koichi, Takao Seishin, Yoshimura Takaaki, Aoyama Hidefumi, Shimizu Shinichi
日本医学放射線学会学術集会抄録集, 80回, S193, S194, (公社)日本医学放射線学会, Mar. 2021
English - The Impact of Daily Urinary Volume Variations and Prostate Volume on Prostate Position During Radiotherapy(和訳中)
Nishioka Kentaro, Hashimoto Takayuki, Yokota Isao, Katoh Norio, Kinoshita Rumiko, Yasuda Koichi, Takao Seishin, Yoshimura Takaaki, Aoyama Hidefumi, Shimizu Shinichi
日本医学放射線学会学術集会抄録集, 80回, S193, S194, (公社)日本医学放射線学会, Mar. 2021
English - Are simple verbal instructions sufficient to ensure that bladder volume does not deteriorate prostate position reproducibility during spot scanning proton therapy?
Kentaro Nishioka, Kento Gotoh, Takayuki Hashimoto, Takashige Abe, Takahiro Osawa, Ryuji Matsumoto, Isao Yokota, Norio Katoh, Rumiko Kinoshita, Koichi Yasuda, Toshiaki Yakabe, Takaaki Yoshimura, Seishin Takao, Nobuo Shinohara, Hidefumi Aoyama, Shinichi Shimizu, Hiroki Shirato
BJR|Open, 3, 1, 20210064, 20210064, British Institute of Radiology, Jan. 2021, [International Magazine]
English, Scientific journal,Objectives: The purpose of this study is to investigate whether verbal instructions are sufficient for bladder volume (BV) control not to deteriorate prostate position reproducibility in image-guided spot scanning proton therapy (SSPT) for localized prostate cancer.Methods: A total of 268 treatment sessions in 12 consecutive prostate cancer patients who were treated with image-guided SSPT with fiducial markers were retrospectively analyzed. In addition to strict rectal volume control procedures, simple verbal instructions to void urine one hour before the treatment were used here. The BV was measured by a Bladder Scan just before the treatment, and the prostate motion was measured by intraprostatic fiducial markers and two sets of X-ray fluoroscopy images. The correlation between the BV change and prostate motion was assessed by linear mixed-effects models and systematic and random errors according to the reproducibility of the BV.Results: The mean absolute BV change during treatment was from −98.7 to 86.3 ml (median 7.1 ml). The mean absolute prostate motion of the patients in the left-right direction was −1.46 to 1.85 mm; in the cranial-caudal direction it was −6.10 to 3.65 mm, and in the anteroposterior direction −1.90 to 5.23 mm. There was no significant relationship between the BV change and prostate motion during SSPT. The early and late genitourinary and gastrointestinal toxicity was minimal with a minimum follow up of 4.57 years.Conclusions: Simple verbal instructions about urination was suggested to be sufficient to control the BV not to impact on the prostate motion and clinical outcomes in image-guided SSPT. Careful attention to BV change is still needed when the seminal vesicle is to be treated.Advances in knowledge: Our data demonstrated that there was no apparent relationship between BV changes and prostate position reproducibility and simple verbal instruction about urination could be sufficient for image-guided SSPT. - Construction of a detachable artificial trachea model for three age groups for use in an endotracheal suctioning training environment simulator.
Takaaki Yoshimura, Noriyo Colley, Shunsuke Komizunai, Shinji Ninomiya, Satoshi Kanai, Atsushi Konno, Koichi Yasuda, Hiroshi Taguchi, Takayuki Hashimoto, Shinichi Shimizu
PloS one, 16, 3, e0249010, 2021, [International Magazine]
English, Scientific journal, Tracheal suctioning is an important procedure to maintain airway patency by removing secretions. Today, suctioning operators include not only medical staff, but also family caregivers. The use of a simulation system has been noted to be the most effective way to learn the tracheal suctioning technique for operators. While the size of the trachea varies across different age groups, the artificial trachea model in the simulation system has only one fixed model. Thus, this study aimed to construct multiple removable trachea models according to different age groups. We enrolled 20 patients who had previously received proton beam therapy in our institution and acquired the treatment planning computed tomography (CT) image data. To construct the artificial trachea model for three age groups (children, adolescents and young adults, and adults), we analyzed the three-dimensional coordinates of the entire trachea, tracheal carina, and the end of the main bronchus. We also analyzed the diameter of the trachea and main bronchus. Finally, we evaluated the accuracy of the model by analyzing the difference between the constructed model and actual measurements. The trachea model was 8 cm long for children and 12 cm for adolescents and young adults, and for adults. The angle between the trachea and bed was about 20 degrees, regardless of age. The mean model accuracy was less than 0.4 cm. We constructed detachable artificial trachea models for three age groups for implementation in the endotracheal suctioning training environment simulator (ESTE-SIM) based on the treatment planning CT image. Our constructed artificial trachea models will be able to provide a simulation environment for various age groups in the ESTE-SIM. - Diagnostic Capability of Cerebrospinal Fluid-Placental Alkaline Phosphatase Value in Intracranial Germ Cell Tumor.
Michinari Okamoto, Shigeru Yamaguchi, Yukitomo Ishi, Hiroaki Motegi, Takashi Mori, Takayuki Hashimoto, Yukayo Terashita, Shinsuke Hirabayashi, Minako Sugiyama, Akihiro Iguchi, Yuko Cho, Atsushi Manabe, Kiyohiro Houkin
Oncology, 99, 1, 23, 31, 2021, [International Magazine]
English, Scientific journal, OBJECTIVE: Most types of intracranial germ cell tumors (IGCTs) are sensitive to chemoradiation. However, biopsy specimens are usually small and thus cannot be used for obtaining an accurate pathological diagnosis. Recently, the cerebrospinal fluid (CSF) placental alkaline phosphatase (PLAP) value has been considered a new biomarker of IGCTs. The present study aimed to evaluate the discriminatory characteristics of the CSF-PLAP value upon diagnosis and at the time of recurrence in patients with IGCTs. METHODS: Between 2015 and 2019, this study included 37 patients with tumors located in the intraventricular and/or periventricular region. The CSF-PLAP level was assessed before the patients received any treatment. The PLAP level was evaluated during and after first-line chemoradiotherapy in 7 patients with IGCTs. The CSF-PLAP values were compared according to histological diagnosis, and the correlation between these values and radiographical features was assessed. The CSF-PLAP values of 6 patients with IGCTs with suspected recurrence were evaluated based on neuroimaging findings. RESULTS: The CSF-PLAP values were significantly higher in patients with IGCTs than in those with other types of brain tumor (n = 19 vs. 18; median: 359.0 vs. <8.0 pg/mL). The specificity and sensitivity were 88 and 95%, respectively, with a cutoff value of 8.0 pg/mL. In patients with IGCT, the CSF-PLAP value was higher in patients with germinoma than in those with nongerminomatous germ cell tumors (n = 12 vs. 7; median: 415.0 vs. 359.0 pg/mL). Regarding the time course, the CSF-PLAP value decreased to below the detection limit after the reception of first-line chemoradiotherapy in all 7 patients. A significant correlation was observed between the initial CSF-PLAP value and the tumor reduction volume after receiving first-line chemoradiotherapy (p < 0.0003, R2 = 0.6165, logY = 1.202logX - 1.727). Among the patients with suspected IGCT recurrence (n = 6), the CSF-PLAP value was high in patients with recurrence (n = 3; median: 259.0 pg/mL), and that in patients (n = 3) without recurrence was below the lower detection limit. CONCLUSIONS: The CSF-PLAP level is a useful biomarker during the initial diagnosis of IGCTs and at the time of recurrence. It may be associated with the volume of germinomatous components of tumors. - Quantitative analysis of treatments using real-time image gated spot-scanning with synchrotron-based proton beam therapy system log data.
Takaaki Yoshimura, Shinichi Shimizu, Takayuki Hashimoto, Kentaro Nishioka, Norio Katoh, Hiroshi Taguchi, Koichi Yasuda, Taeko Matsuura, Seishin Takao, Masaya Tamura, Sodai Tanaka, Yoichi M Ito, Yuto Matsuo, Hiroshi Tamura, Kenji Horita, Kikuo Umegaki, Hiroki Shirato
Journal of applied clinical medical physics, 21, 12, 10, 19, Dec. 2020, [International Magazine]
English, Scientific journal, A synchrotron-based real-time image gated spot-scanning proton beam therapy (RGPT) system with inserted fiducial markers can irradiate a moving tumor with high accuracy. As gated treatments increase the beam delivery time, this study aimed to investigate the frequency of intra-field adjustments corresponding to the baseline shift or drift and the beam delivery efficiency of a synchrotron-based RGPT system. Data from 118 patients corresponding to 127 treatment plans and 2810 sessions between October 2016 and March 2019 were collected. We quantitatively analyzed the proton beam delivery time, the difference between the ideal beam delivery time based on a simulated synchrotron magnetic excitation pattern and the actual treatment beam delivery time, frequency corresponding to the baseline shift or drift, and the gating efficiency of the synchrotron-based RGPT system according to the proton beam delivery machine log data. The mean actual beam delivery time was 7.1 min, and the simulated beam delivery time in an ideal environment with the same treatment plan was 2.9 min. The average difference between the actual and simulated beam delivery time per session was 4.3 min. The average frequency of intra-field adjustments corresponding to baseline shift or drift and beam delivery efficiency were 21.7% and 61.8%, respectively. Based on our clinical experience with a synchrotron-based RGPT system, we determined the frequency corresponding to baseline shift or drift and the beam delivery efficiency using the beam delivery machine log data. To maintain treatment accuracy within ± 2.0 mm, intra-field adjustments corresponding to baseline shift or drift were required in approximately 20% of cases. Further improvements in beam delivery efficiency may be realized by shortening the beam delivery time. - Automatic Bladder Delineation on MR Images Using a Convolution Neural Network for Online Image-Guided Radiotherapy
K. Nishioka, Y. Nomura, T. Hashimoto, R. Kinoshita, N. Katoh, H. Taguchi, K. Yasuda, T. Mori, Y. Uchinami, M. Otsuka, T. Matsuura, S. Takao, R. Suzuki, S. Tanaka, T. Yoshimura, H. Aoyama, S. Shimizu
International Journal of Radiation Oncology*Biology*Physics, 108, 3, e288, e289, Elsevier BV, Nov. 2020
Scientific journal - 画像誘導治療の今後について 画像誘導陽子線治療の将来展望
田口 大志, 橋本 孝之, 加藤 徳雄, 木下 留美子, 安田 耕一, 西岡 健太郎, 森 崇, 打浪 雄介, 宮本 直樹, 高尾 聖心, 清水 伸一, 青山 英史
日本癌治療学会学術集会抄録集, 58回, SY14, 3, (一社)日本癌治療学会, Oct. 2020
English - 【前立腺癌診療update-最新の診断と治療-】診断と治療 陽子線治療
清水 伸一, 西岡 健太郎, 橋本 孝之
日本臨床, 78, 6, 977, 982, (株)日本臨床社, Jun. 2020
Japanese - 【泌尿器がんの新しい放射線治療戦略】前立腺がん 前立腺がんの陽子線治療
清水 伸一, 橋本 孝之, 西岡 健太郎
泌尿器科, 11, 4, 386, 391, (有)科学評論社, Apr. 2020
Japanese - Analysis of treatment process time for real-time-image gated-spot-scanning proton-beam therapy (RGPT) system.
Takaaki Yoshimura, Shinichi Shimizu, Takayuki Hashimoto, Kentaro Nishioka, Norio Katoh, Tetsuya Inoue, Hiroshi Taguchi, Koichi Yasuda, Taeko Matsuura, Seishin Takao, Masaya Tamura, Yoichi M Ito, Yuto Matsuo, Hiroshi Tamura, Kenji Horita, Kikuo Umegaki, Hiroki Shirato
Journal of applied clinical medical physics, 21, 2, 38, 49, Feb. 2020, [Peer-reviewed], [International Magazine]
English, Scientific journal, We developed a synchrotron-based real-time-image gated-spot-scanning proton-beam therapy (RGPT) system and utilized it to clinically operate on moving tumors in the liver, pancreas, lung, and prostate. When the spot-scanning technique is linked to gating, the beam delivery time with gating can increase, compared to that without gating. We aim to clarify whether the total treatment process can be performed within approximately 30 min (the general time per session in several proton therapy facilities), even for gated-spot-scanning proton-beam delivery with implanted fiducial markers. Data from 152 patients, corresponding to 201 treatment plans and 3577 sessions executed from October 2016 to June 2018, were included in this study. To estimate the treatment process time, we utilized data from proton beam delivery logs during the treatment for each patient. We retrieved data, such as the disease site, total target volume, field size at the isocenter, and the number of layers and spots for each field, from the treatment plans. We quantitatively analyzed the treatment process, which includes the patient load (or setup), bone matching, marker matching, beam delivery, patient unload, and equipment setup, using the data obtained from the log data. Among all the cases, 90 patients used the RGPT system (liver: n = 34; pancreas: n = 5; lung: n = 4; and prostate: n = 47). The mean and standard deviation (SD) of the total treatment process time for the RGPT system was 30.3 ± 7.4 min, while it was 25.9 ± 7.5 min for those without gating treatment, excluding craniospinal irradiation (CSI; head and neck: n = 16, pediatric: n = 31, others: n = 15); for CSI (n = 11) with two or three isocenters, the process time was 59.9 ± 13.9 min. Our results demonstrate that spot-scanning proton therapy with a gating function can be achieved in approximately 30-min time slots. - The updated outcomes of bladder-preserving trimodal therapy using a real-time tumor-tracking radiotherapy system for patients with muscle-invasive bladder cancer.
Haruka Miyata, Takahiro Osawa, Takashige Abe, Hiroshi Kikuchi, Ryuji Matsumoto, Satoru Maruyama, Kentaro Nishioka, Shinichi Shimizu, Takayuki Hashimoto, Hiroki Shirato, Nobuo Shinohara
Japanese journal of clinical oncology, 19 Jan. 2020, [Peer-reviewed], [International Magazine]
English, OBJECTIVE: Bladder-preserving trimodal therapy is recognized as a promising alternative treatment for muscle-invasive bladder cancer. We report the updated outcomes of muscle-invasive bladder cancer patients that were treated using our treatment protocol, which involves radiotherapy delivered with a real-time tumor-tracking radiotherapy system. METHODS: Thirty-eight patients who were diagnosed with T2-T4N0M0 bladder cancer between 1998 and 2016 and had clinically inoperable disease or refused to undergo surgery were enrolled. The treatment protocol included maximal transurethral resection followed by whole-bladder radiotherapy (40 Gy). Concurrent nedaplatin-based chemotherapy was administered to patients with adequate renal function. At the time of the first evaluation (via transurethral resection of the tumor bed), fiducial markers were endoscopically inserted into the bladder wall around the tumor. A boost of 25 Gy was administered using the real-time tumor-tracking radiotherapy system. The second evaluation (via transurethral resection of the tumor bed) was performed 6 months after the start of treatment. The Kaplan-Meier method and Cox hazards analysis were used to analyze overall survival and cancer-specific survival. RESULTS: The median duration of the follow-up period was 28 months (range: 3-161 months). The 5- and 10-year overall survival rates were 54.9 and 41.2%, respectively. Twenty-five (65.8%) and twenty (74.1%) patients had achieved complete responses to chemoradiation at the first and second evaluations, respectively. In univariate and multivariate analyses, performance status was found to be significantly associated with overall survival [P = 0.03, hazard ratio: 3.48, 95% confidence interval: 1.15-10.6] and cancer-specific survival [P = 0.02, hazard ratio: 4.57, 95% confidence interval: 1.32-16.9], and sex was shown to be significantly associated with cancer-specific survival [P = 0.03, hazard ratio: 3.07, 95% confidence interval: 1.09-8.30]. CONCLUSIONS: Our bladder-preserving trimodal therapy protocol, which involves the use of a real-time tumor-tracking radiotherapy system, produced an acceptable overall survival rate. This therapy is a reasonable alternative for patients that are medically unfit for or do not want to undergo cystectomy. - The urethral position may shift due to urethral catheter placement in the treatment planning for prostate radiation therapy.
Yasuhiro Dekura, Kentaro Nishioka, Takayuki Hashimoto, Naoki Miyamoto, Ryusuke Suzuki, Takaaki Yoshimura, Ryuji Matsumoto, Takahiro Osawa, Takashige Abe, Yoichi M Ito, Nobuo Shinohara, Hiroki Shirato, Shinichi Shimizu
Radiation oncology (London, England), 14, 1, 226, 226, 12 Dec. 2019, [Peer-reviewed], [International Magazine]
English, PURPOSE: To determine the best method to contour the planning organ at risk volume (PRV) for the urethra, this study aimed to investigate the displacement of a Foley catheter in the urethra with a soft and thin guide-wire. METHODS: For each patient, the study used two sets of computed tomography (CT) images for radiation treatment planning (RT-CT): (1) set with a Foley urethral catheter (4.0 mm diameter) plus a guide-wire (0.46 mm diameter) in the first RT-CT and (2) set with a guide-wire alone in the second CT recorded 2 min after the first RT-CT. Using three fiducial markers in the prostate for image fusion, the displacement between the catheter and the guide-wire in the prostatic urethra was calculated. In 155 consecutive patients treated between 2011 and 2017, 5531 slices of RT-CT were evaluated. RESULTS: Assuming that ≥3.0 mm of difference between the catheter and the guide-wire position was a significant displacement, the urethra with the catheter was displaced significantly from the urethra with the guide-wire alone in > 20% of the RT-CT slices in 23.2% (36/155) of the patients. The number of patients who showed ≥3.0 mm anterior displacement with the catheter in ≥20% RT-CT slices was significantly larger at the superior segment (38/155) than at the middle (14/155) and inferior segments (18/155) of the prostatic urethra (p < 0.0167). CONCLUSIONS: The urethral position with a Foley catheter is different from the urethral position with a thin and soft guide-wire in a significant proportion of the patients. This should be taken into account for the PRV of the urethra to ensure precise radiotherapy such as in urethra-sparing radiotherapy. - 高リスク前立腺癌に対するロボット支援前立腺全摘除術と放射線療法の臨床的比較検討
松本 隆児, 古御堂 純, 宮田 遥, 菊地 央, 大澤 崇宏, 安部 崇重, 西岡 健太郎, 橋本 孝之, 清水 伸一, 篠原 信雄
日本泌尿器内視鏡学会総会, 33回, P, 1, (一社)日本泌尿器内視鏡・ロボティクス学会, Nov. 2019
Japanese - 高リスク前立腺癌に対するロボット支援前立腺全摘除術と放射線療法の臨床的比較検討
松本 隆児, 古御堂 純, 宮田 遥, 菊地 央, 大澤 崇宏, 安部 崇重, 西岡 健太郎, 橋本 孝之, 清水 伸一, 篠原 信雄
日本泌尿器内視鏡学会総会, 33回, P, 1, (一社)日本泌尿器内視鏡・ロボティクス学会, Nov. 2019
Japanese - Initial Clinical Outcomes of Real-Time-Image Gated Spot-Scanning Proton Beam Therapy for Hepatocellular Carcinomas
N. Katoh, Y. Uchinami, D. Abo, S. Takao, T. Inoue, H. Taguchi, R. Morita, T. Soyama, T. Hashimoto, R. Onimaru, A. Prayongrat, M. Tamura, T. Matsuura, S. Shimizu, H. Shirato
International Journal of Radiation Oncology*Biology*Physics, 105, 1, E222, E223, Elsevier BV, Sep. 2019
Scientific journal - 頭蓋内胚細胞腫瘍における放射線化学療法後のsalvage surgeryに関する病理所見からの検討
山口 秀, 茂木 洋晃, 伊師 雪友, 岡本 迪成, 井口 晶裕, 長 祐子, 杉山 未奈子, 橋本 孝之, 岡田 宏美, 寳金 清博
Brain Tumor Pathology, 36, Suppl., 096, 096, 日本脳腫瘍病理学会, May 2019
Japanese - Clinical experience of craniospinal intensity-modulated spot-scanning proton therapy using large fields for central nervous system medulloblastomas and germ cell tumors in children, adolescents, and young adults.
Hashimoto T, Shimizu S, Takao S, Terasaka S, Iguchi A, Kobayashi H, Mori T, Yoshimura T, Matsuo Y, Tamura M, Matsuura T, Ito YM, Onimaru R, Shirato H
Journal of radiation research, 60, 4, 527, 537, May 2019, [Peer-reviewed], [International Magazine]
English, Scientific journal, The outcomes of intensity-modulated proton craniospinal irradiation (ipCSI) are unclear. We evaluated the clinical benefit of our newly developed ipCSI system that incorporates two gantry-mounted orthogonal online X-ray imagers with a robotic six-degrees-of-freedom patient table. Nine patients (7-19 years old) were treated with ipCSI. The prescribed dose for CSI ranged from 23.4 to 36.0 Gy (relative biological effectiveness) in 13-20 fractions. Four adolescent and young adult (AYA) patients (15 years or older) were treated with vertebral-body-sparing ipCSI (VBSipCSI). Myelosuppression following VBSipCSI was compared with that of eight AYA patients treated with photon CSI at the same institution previously. The mean homogeneity index (HI) in the nine patients was 0.056 (95% confidence interval: 0.044-0.068). The mean time from the start to the end of all beam delivery was 37 min 39 s ± 2 min 24 s (minimum to maximum: 22 min 49 s - 42 min 51 s). The nadir white blood cell, hemoglobin, and platelet levels during the 4 weeks following the end of the CSI were significantly higher in the VBSipCSI group than in the photon CSI group (P = 0.0071, 0.0453, 0.0024, respectively). The levels at 4 weeks after the end of CSI were significantly higher in the VBSipCSI group than in the photon CSI group (P = 0.0023, 0.0414, 0.0061). Image-guided ipCSI was deliverable in a reasonable time with sufficient HI. Using VBSipCSI, AYA patients experienced a lower incidence of serious acute hematological toxicity than AYA patients treated with photon CSI. - Big Data Analysis of Treatment Process Time for the Real-Time-Image Gated-Spot-Scanning Proton-Beam Therapy (RGPT) System
T. Yoshimura, S. Shimizu, T. Hashimoto, N. Katoh, T. Inoue, K. Nishioka, T. Matsuura, S. Takao, M. Tamura, H. Tamura, K. Horita, K. Umegaki, H. Shirato
International Journal of Radiation Oncology*Biology*Physics, 102, 3, e501, e502, Elsevier BV, Nov. 2018
Scientific journal - Analysis of Beam Delivery Times and Dose Rates for the Treatment of Mobile Tumors Using Real Time Image Gated Spot-Scanning Proton Beam Therapy
S. Shimizu, T. Yoshimura, N. Katoh, T. Inoue, T. Hashimoto, K. Nishioka, S. Takao, T. Matsuura, N. Miyamoto, Y.M. Ito, K. Umegaki, H. Shirato
International Journal of Radiation Oncology*Biology*Physics, 102, 3, S182, S183, Elsevier BV, Nov. 2018
Scientific journal - Determination of the urethra position for accurate radiation therapy of prostate cancers
Dekura Yasuhiro, Nishioka Kentaro, Hashimoto Takayuki, Miyamoto Naoki, Suzuki Ryusuke, Matsumoto Ryuji, Osawa Takahiro, Abe Takashige, Maruyama Satoru, Shinohara Nobuo, Shirato Hiroki, Shimizu Shinichi
INTERNATIONAL JOURNAL OF UROLOGY, 25, 445, 445, Oct. 2018, [Peer-reviewed]
English - Long-term Outcomes of Tri-modality Therapy using a real-time tumor-tracking radiotherapy system for Patients with Muscle-invasive Bladder Cancer
Miyata Haruka, Osawa Takahiro, Matsumoto Ryuji, Abe Takashige, Maruyama Satoru, Nishioka Kentaro, Shimizu Shinichi, Hashimoto Takayuki, Shirato Hiroki, Shinohara Nobuo
INTERNATIONAL JOURNAL OF UROLOGY, 25, 321, Oct. 2018, [Peer-reviewed] - 前立腺癌治療の新たな展開:ハイリスク前立腺癌に対する拡大手術、粒子線治療、ネオアジュバント治療 ハイリスク前立腺がんに対する強度変調放射線治療・陽子線治療 現状と可能性
清水 伸一, 橋本 孝之, 西岡 健太郎, 安部 崇重, 大澤 崇宏, 松本 隆児, 松浦 妙子, 宮本 直樹, 高尾 聖心, 鈴木 隆介, 梅垣 菊男, 篠原 信雄, 白土 博樹
日本癌治療学会学術集会抄録集, 56回, SY5, 2, (一社)日本癌治療学会, Oct. 2018
English - Investigation of energy absorption by clustered gold nanoparticles
Jihun Kwon, Kenneth Sutherland, Anastasia Makarova, Taeko Matsuura, Takayuki Hashimoto, Hao Peng, Toshiyuki Toshito, Kikuo Umegaki, Hiroki Shirato, Shinichi Shimizu
Nuclear Instruments and Methods in Physics Research, Section B: Beam Interactions with Materials and Atoms, 429, 34, 41, 15 Aug. 2018, [Peer-reviewed]
Scientific journal - Prospective study to evaluate the safety of the world-first spot-scanning dedicated, small 360-degree gantry, synchrotron-based proton beam therapy system.
Nishioka K, Prayongrat A, Ono K, Onodera S, Hashimoto T, Katoh N, Inoue T, Kinoshita R, Yasuda K, Mori T, Onimaru R, Shirato H, Shimizu S
Journal of radiation research, 59, suppl_1, i63, i71, Mar. 2018, [Peer-reviewed], [International Magazine]
English, Scientific journal, This is a report of a single-institution prospective study evaluating the safety of a spot-scanning dedicated, small 360-degree gantry, synchrotron-based proton beam therapy (PBT) system. Data collection was performed for 56 patients with 59 treatment sites who received proton beam therapy at Hokkaido University Hospital between March 2014 and July 2015. Forty-one patients were male and 15 were female. The median age was 66 years. The primary lesion sites were prostate (n = 17), bone/soft tissue (n = 10), liver (n = 7), lung (n = 6), central nervous system (n = 5), colon (n = 2), pancreas (n = 2), kidney (n = 2) and others (n = 5). Chemotherapy was administered in 11 patients. The prescribed total dose was from 20 to 76 GyE (Radiobiological equivalent dose, RBE = 1.1), with the median dose of 65 GyE in 4 to 35 fractions. No PBT-related Common Terminology Criteria for Adverse Events Grade 4 or 5 toxicities were observed; the incidence of early PBT-related Grade 4 adverse events was 0% (95% confidence interval 0 to 6.38%). The most common Grade 3 toxicities were hematologic toxicity (12.5%) unlikely to be related to the PBT. One patient developed a left femoral neck fracture (Grade 3) at 14.5 months after PBT for chondrosarcoma of the left pelvis. The pathological findings showed no other malignancies, suggesting that it was possibly related to the PBT. In conclusion, the spot-scanning dedicated, synchrotron-based PBT system is feasible, but further studies on its long-term safety and efficacy are warranted. - 北海道大学病院の小児がん陽子線治療に対する取り組み
橋本孝之, 井口晶裕, 寺坂俊介, 杉山美奈子, 大島淳二郎, 山口秀, 小林浩之, 長祐子, 清水伸一, 鬼丸力也, 白土博樹
日本小児科学会雑誌, 121, 5, 914‐915, 915, (公社)日本小児科学会, 01 May 2017
Japanese - 粒子線治療装置等が地域経済へ及ぼす影響
畔木智己, 橋本孝之, 清水伸一, 土屋和彦, 鬼丸力也, 白土博樹
Japanese Journal of Radiology, 35, Supplement, 4, 4, (公社)日本医学放射線学会, 25 Feb. 2017
Japanese - 乳房温存術後接線照射後にFitz‐Hugh‐Curtis症候群様の肝周囲炎を来した1例
出倉康裕, 森崇, 西川由記子, 木下留美子, 橋本孝之, 白土博樹, 西岡健太郎, 清水伸一, 細田充主, 山下啓子
Japanese Journal of Radiology, 35, Supplement, 4, 4, (公社)日本医学放射線学会, 25 Feb. 2017
Japanese - Targeting integrins with RGD-conjugated gold nanoparticles in radiotherapy decreases the invasive activity of breast cancer cells
Ping-Hsiu Wu, Yasuhito Onodera, Yuki Ichikawa, Erinn B. Rankin, Amato J. Giaccia, Yuko Watanabe, Wei Qian, Takayuki Hashimoto, Hiroki Shirato, Jin-Min Nam
INTERNATIONAL JOURNAL OF NANOMEDICINE, 12, 5069, 5085, 2017, [Peer-reviewed]
English, Scientific journal - 前立腺癌の放射線治療時における尿量の変動の解析
後藤謙斗, 西岡健太郎, 松崎有華, 松浦妙子, 高尾聖心, 橋本孝之, 木下留美子, 西川由記子, 清水伸一, 白土博樹
日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集, 30th, 55, 2017
Japanese - 気管内挿管下全身麻酔管理で陽子線治療を実施した小児がんの2症例(Proton beam therapy for pediatric cancer with endotracheal intubation under the general anesthesia: A report of two cases)
橋本 孝之, 敦賀 健吉, 小林 浩之, 井口 晶裕, 本多 昌平, 杉山 未奈子, 安田 耕一, 宮城 久之, 山口 秀, 藤田 憲明, 大島 淳二郎, 長 祐子, 鬼丸 力也, 清水 伸一, 寺坂 俊介, 森本 裕二, 白土 博樹
日本小児血液・がん学会雑誌, 53, 4, 366, 366, (NPO)日本小児血液・がん学会, Nov. 2016
English - 椎体IMRTとその精度に関する研究
安田 耕一, 清水 伸一, 橋本 孝之, Sutherland Ken, 白土 博樹, 土屋 和彦, 加藤 徳雄, 鬼丸 力也, 木下 留美子, 井上 哲也, 西岡 健太郎, 西川 由記子, 森 崇, 原田 慶一, 原田 八重, 鈴木 隆介, 寅松 千枝, 松浦 妙子, 高尾 聖心, 宮本 直樹, 伊藤 陽一
Japanese Journal of Radiology, 34, Suppl., 5, 5, (公社)日本医学放射線学会, Feb. 2016
Japanese - キャンサーボードが機能した1症例
遠藤 将吾, 寺坂 俊介, 小林 浩之, 山口 秀, 茂木 洋晃, 金子 貞洋, 井口 晶裕, 長 祐子, 大島 淳二郎, 寺坂 友佳代, 杉山 未奈子, 橋本 孝之, 鬼丸 力也, 清水 伸一, 有賀 正, 白戸 博樹, 寳金 清博
日本小児血液・がん学会雑誌, 52, 3, 343, 343, (NPO)日本小児血液・がん学会, Oct. 2015
Japanese - Proton beam therapy for unresectable intrahepatic cholangiocarcinoma
Ohkawa,Ayako, Mizumoto,Masashi, Ishikawa,Hitoshi, Abei,Masato, Fukuda,Kuniaki, Hashimoto,Takayuki, Sakae,Takeji, Tsuboi,Koji, Okumura,Toshiyuki, Sakurai,Hideyuki
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 30, 5, 957, 963, WILEY-BLACKWELL, May 2015, [Peer-reviewed]
English, Scientific journal - Comparison of adverse effects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose-volume histogram analysis
MAKISHIMA,HIROKAZU, ISHIKAWA,HITOSHI, TERUNUMA,TOSHIYUKI, HASHIMOTO,TAKAYUKI, YAMANASHI,KOICHI, SEKIGUCHI,TAKAO, MIZUMOTO,MASASHI, OKUMURA,TOSHIYUKI, SAKAE,TAKEJI, SAKURAI,HIDEYUKI
Journal of Radiation Research, 56, 3, 568, 576, OXFORD UNIV PRESS, May 2015, [Peer-reviewed]
English, Scientific journal, Cardiopulmonary late toxicity is of concern in concurrent chemoradiotherapy （CCRT）for esophageal cancer.The aim of this study was to examine the benefit of proton beam therapy（PBT）using clinical data and adaptive dosevolume histogram（DVH）analysis.The subjects were 44 patients with esophageal cancer who underwent definitive CCRT using X-rays （n=19）or protons （n=25）.Experimental recalculation using protons was performed for the patient actually treated with X-rays ,and vice versa.Target coverage and dose constraints of normal tissues were conserved.Lung V5-V20,mean lung dose （MLD）,and heart V30-V50 were compared for risk organ doses between experimental plans and actual treatment plans.Potential toxicity was estimated using protons in patients actually treated with X-rays,and vice versa. Pulmonary events of Grade ≧2 occurred in 8/44 cases（18%）,and cardiac events were seen in 11 cases （25%）.Risk organ doses in patients with events of Grade ≧2 were significantly higher than for those with events of Grade ≦1.Risk organ doses were lower in proton plans compared with X-ray plans.All patients suffering toxicity who were treated with X-rays （n=13 - Proton beam therapy combined with concurrent chemotherapy for esophageal cancer
Ishikawa,Hitoshi, Hashimoto,Takayuki, Moriwaki,Toshikazu, Hyodo,Ichinosuke, Hisakura,Katsuji, Terashima,Hideo, Ohkohchi,Nobuhiro, Ohno,Toshiki, Makishima,Hirokazu, Mizumoto,Masashi, Ohnishi,Kayoko, Okumura,Toshiyuki, Sakurai,Hideyuki
Anticancer research, 35, 3, 1757, 1762, INT INST ANTICANCER RESEARCH, Mar. 2015
English, Scientific journal, The aim of the present study was to evaluate the outcomes of proton beam therapy (PBT) concurrently combined with chemotherapy consisting of cisplatin and 5-fluorouracil for esophageal cancer. Forty consecutive patients (stage I in 16 patients, II in 9 and III in 15) treated between 2008 and 2012 were evaluated. A total dose of 60 Gray equivalents (GyE) in 30 fractions was delivered, and an additional boost of 4-10 GyE was given when residual tumors were suspected. The median follow-up time was 24 months (range=7-66 months). No cardio-pulmonary toxicities of grade 3 or higher were observed. Recurrences were observed in 16 patients, and the 2-year rates of disease-specific survival and locoregional control were 77% and 66%, respectively. Irrespective of the small sample size and short follow-up time of the study, proton beam therapy combined with chemo therapy seems to be feasible for esophageal cancer. - Dose distribution of electrons from gold nanoparticles by proton beam irradiation
Jihun Kwon, Kenneth Sutherland, Takayuki Hashimoto, Hiroyuki Date
International Journal of Medical Physics, Clinical Engineering and Radiation Oncology, 2015, 4, 49, 53, 2015, [Peer-reviewed]
English, Scientific journal - 脳原発横紋筋肉腫に対する集学的治療の経験
長 祐子, 杉山 未奈子, 寺下 友佳代, 大島 淳二郎, 佐藤 智信, 井口 晶裕, 有賀 正, 小林 浩之, 寺坂 俊介, 橋本 孝之, 高桑 恵美
日本小児血液・がん学会雑誌, 51, 4, 282, 282, (一社)日本小児血液・がん学会, Oct. 2014
Japanese - Proton Beam Therapy Combined With Concurrent Chemotherapy for Esophageal Cancer
Ishikawa.H, Okumura.T, Ohno.T, Makishima.H, Ohnishi.K, Mizumoto.M, Aihara.T, Numajiri.H, Hashimoto.T, Sakurai.H
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90, 1, S346, S346, ELSEVIER SCIENCE INC, Sep. 2014, [Peer-reviewed]
English, Scientific journal - 北海道大学病院陽子線治療センターの小児陽子線治療開始準備状況
橋本 孝之, 清水 伸一, 鬼丸 力也, 大島 淳二郎, 長 祐子, 井口 晶裕, 山口 秀, 小林 浩之, 寺坂 俊介, 岡田 忠雄, 本田 昌平, 武冨 紹信, 岡村 麗香, 中村 宏治, 白土 博樹
日本小児血液・がん学会雑誌, 51, 2, 183, 183, (NPO)日本小児血液・がん学会, Jun. 2014
Japanese - Outcomes and Prognostic Factors for Recurrence After High-Dose Proton Beam Therapy for Centrally and Peripherally Located Stage I None-Small-Cell Lung Cancer
Ayae Kanemoto, Toshiyuki Okumura, Hitoshi Ishikawa, Masashi Mizumoto, Yoshiko Oshiro, Koichi Kurishima, Shinsuke Homma, Takayuki Hashimoto, Ayako Ohkawa, Haruko Numajiri, Toshiki Ohno, Takashi Moritake, Koji Tsuboi, Takeji Sakae, Hideyuki Sakurai
CLINICAL LUNG CANCER, 15, 2, E7, E12, Mar. 2014, [Peer-reviewed]
English, Scientific journal - A phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma
Abei, Masato, Okumura, Toshiyuki, Fukuda, Kuniaki, Hashimoto, Takayuki, Araki, Masahiro, Ishige, Kazunori, Hyodo, Ichinosuke, Kanemoto, Ayae, Numajiri, Haruko, Mizumoto, Masashi, Sakae, Takeji, Sakurai, Hideyuki, Zenkoh, Junko, Ariungerel, Gerelchuluun, Sogo, Yu, Ito, Atsuo, Ohno, Tadao, Tsuboi, Koji
RADIATION ONCOLOGY, 8, 239, BIOMED CENTRAL LTD, Oct. 2013, [Peer-reviewed]
English, Scientific journal - Preliminary Results of Concurrent Chemoradiation Therapy Using Proton Beam Therapy for Esophageal Cancer
Ishikawa,H, Hashimoto,T, Mizumoto,M, Ohno,T, Makishima,H, Takizawa,D, Sugawara,K, Okumura,T, Sakurai,H
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87, 2::S, S294, S294, ELSEVIER SCIENCE INC, Oct. 2013, [Peer-reviewed]
English, Scientific journal - Long-term Survival in Patients With Hepatocellular Carcinoma Initially Treated With Definitive Proton Beam Therapy
Okumura,T, Fukuda,K, Hashimoto,T, Mizumoto,M, Ishikawa,H, Sakae,T, Abei,M, Tsuboi,K, Sakurai,H
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87, 2::S, S321, S321, ELSEVIER SCIENCE INC, Oct. 2013
English, Scientific journal - 食道扁平上皮癌に対する同時化学療法併用陽子線治療の初期成績
石川 仁, 橋本 孝之, 大野 豊然貴, 水本 斉志, 大西 かよ子, 粟飯原 輝人, 森脇 俊和, 久倉 勝治, 寺島 秀夫, 奥村 敏之, 櫻井 英幸
日本癌治療学会誌, 48, 3, 1178, 1178, (一社)日本癌治療学会, Sep. 2013
Japanese - Comparison of adverse effects of proton and X-ray chemoradiotherapy for oesophageal cancer using an adaptive dose-volume histogram analysis
Makishima,H, Ishikawa,H, Terunuma,T, Hashimoto,T, Yamanashi,K, Sekiguchi,T, Mizumoto,M, Okumura,T, Tsuboi,K, Sakurai,H
EUROPEAN JOURNAL OF CANCER, 49, 2, S576, S576, ELSEVIER SCI LTD, Sep. 2013, [Peer-reviewed]
English, Scientific journal - Phase II Study of Concurrent Chemoradiotherapy at the Dose of 50.4 Gy with Elective Nodal Irradiation for Stage IIIII Esophageal Carcinoma
Ken Kato, Takako Eguchi Nakajima, Yoshinori Ito, Chikatoshi Katada, Hiromichi Ishiyama, Shin-ya Tokunaga, Masahiro Tanaka, Shuichi Hironaka, Takayuki Hashimoto, Takashi Ura, Takeshi Kodaira, Ken-ichi Yoshimura
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 43, 6, 608, 615, Jun. 2013, [Peer-reviewed]
English, Scientific journal - Clinical results of proton beam therapy for advanced neuroblastoma
Yoshiko Oshiro, Masashi Mizumoto, Toshiyuki Okumura, Shinji Sugahara, Takashi Fukushima, Hitoshi Ishikawa, Tomohei Nakao, Takayuki Hashimoto, Koji Tsuboi, Haruo Ohkawa, Michio Kaneko, Hideyuki Sakurai
RADIATION ONCOLOGY, 8, 142, Jun. 2013, [Peer-reviewed]
English, Scientific journal - Dose-volume histogram analysis for risk factors of radiation-induced rib fracture after hypofractionated proton beam therapy for hepatocellular carcinoma
Ayae Kanemoto, Masashi Mizumoto, Toshiyuki Okumura, Hideto Takahashi, Takayuki Hashimoto, Yoshiko Oshiro, Nobuyoshi Fukumitsu, Takashi Moritake, Koji Tsuboi, Takeji Sakae, Hideyuki Sakurai
Acta Oncologica, 52, 3, 538, 544, 3, Apr. 2013, [Peer-reviewed]
English, Scientific journal - Proton beam therapy for unresectable hepatoblastoma in children: Survival in one case
Yoshiko Oshiro, Toshiyuki Okumura, Masashi Mizumoto, Takashi Fukushima, Hitoshi Ishikawa, Takayuki Hashimoto, Koji Tsuboi, Michio Kaneko, Hideyuki Sakurai
Acta Oncologica, 52, 3, 600, 603, 3, Apr. 2013, [Peer-reviewed]
English - Comparison of the Effects of High-Energy Photon Beam Irradiation (10 and 18 MV) on 2 Types of Implantable Cardioverter-Defibrillators
Haruko Hashii, Takayuki Hashimoto, Ayako Okawa, Koichi Shida, Tomonori Isobe, Masahiro Hanmura, Tetsuo Nishimura, Kazutaka Aonuma, Takeji Sakae, Hideyuki Sakurai
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 85, 3, 840, 845, Mar. 2013, [Peer-reviewed]
English, Scientific journal - Reproducibility of image quality for moving objects using respiratory-gated computed tomography: A study using a phantom model
Nobuyoshi Fukumitsu, Masaya Ishida, Toshiyuki Terunuma, Masashi Mizumoto, Takayuki Hashimoto, Takashi Moritake, Toshiyuki Okumura, Takeji Sakae, Koji Tsuboi, Hideyuki Sakurai
Journal of Radiation Research, 53, 6, 945, 953, 6, Nov. 2012, [Peer-reviewed]
English, Scientific journal - Designed-seamless irradiation technique for extended whole mediastinal proton-beam irradiation for esophageal cancer
Noriyuki Okonogi, Takatuki Hashimoto, Masaya Ishida, Toshiki Ohno, Toshiyuki Terunuma, Toshiyuki Okumura, Takeji Sakae, Hideyuki Sakurai
RADIATION ONCOLOGY, 7, Oct. 2012
English, Scientific journal - Verification of beam delivery using fibrosis after proton beam irradiation to the lung tumor
Nobuyoshi Fukumitsu, Yoshiko Oshiro, Takayuki Hashimoto, Toshiyuki Okumura, Masashi Mizumoto, Takashi Moritake, Koji Tsuboi, Takeji Sakae, Hideyuki Sakurai
LUNG CANCER, 77, 1, 83, 88, Jul. 2012, [Peer-reviewed]
English, Scientific journal - 肝細胞癌に対する陽子線治療における予後と治療前肝機能の関連性
水本斉志, 奥村敏之, 橋本孝之, 石川仁, 福田邦明, 安部井誠人, 石毛和紀, 兵頭一之介, 坪井康次, 櫻井英幸
第48回日本肝癌研究会, Jul. 2012, [Peer-reviewed]
Japanese, Research society - Spindle cell sarcoma of the penis: A case report
Tomokazu Kimura, Takehiro Oikawa, Atsushi Ikeda, Takayuki Yoshino, Takahiro Suetomi, Jun Miyazaki, Toru Shimazui, Takayuki Hashimoto, Shintaro Sugita, Masayuki Noguchi, Hiroyuki Nishiyama
Acta Urologica Japonica, 58, 6, 299, 305, 6, Jun. 2012, [Peer-reviewed]
Japanese, Scientific journal - Outcome of T4 (International Union Against Cancer Staging System, 7th edition) or Recurrent Nasal Cavity and Paranasal Sinus Carcinoma Treated With Proton Beam
Nobuyoshi Fukumitsu, Toshiyuki Okumura, Masashi Mizumoto, Yoshiko Oshiro, Takayuki Hashimoto, Ayae Kanemoto, Haruko Hashii, Ayako Ohkawa, Takashi Moritake, Koji Tsuboi, Keiji Tabuchi, Tetsuro Wada, Akira Hara, Hideyuki Sakurai
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 83, 2, 704, 711, Jun. 2012, [Peer-reviewed]
English, Scientific journal - [Advances in highly conformal radiotherapy for prostate cancer: past, current, and future]
Ishikawa Hitoshi, Hashimoto Takayuki, Makishima Hirokazu, Mizumoto Masashi, Okumura Toshiyuki, Sakurai Hideyuki
Igaku butsuri : Nihon Igaku Butsuri Gakkai kikanshi = Japanese journal of medical physics : an official journal of Japan Society of Medical Physics, 32, 3, 138, 147, Japan Society of Medical Physics, Apr. 2012
English, Scientific journal, Recent advance in the field of radiation oncology, especially in medical physics for radiation therapy (RT), has considerably improved treatment outcomes of various cancers including prostate cancer with regard to both of tumor control and morbidity. Three-dimensionally conformal RT with image-guided radiotherapeutic modalities for accurate tumor localization, such as brachytherapy, intensity-modulated radiation therapy (IMRT), and charged particle beam RT can thereby deliver a large dose to the tumor and allow the sparing of surrounding normal tissues. It is thought that prostate cancer is one of representative cancers which have been treated with RT as a curative intent and benefited from novel conformal RT techniques. Because the number of prostate cancer patients has been increasing year by year in Japan as results from wide spread of PSA screening and rapid change in life style, RT has been recently playing much more important roles in the curative treatment for patients with prostate cancer. Hence, we will review the outcomes of RT for prostate cancer and introduce the benefit of modern RT modalities from clinical aspect. In addition, our future prospect to further yield bett - Evaluation of Liver Function After Proton Beam Therapy for Hepatocellular Carcinoma
Masashi Mizumoto, Toshiyuki Okumura, Takayuki Hashimoto, Kuniaki Fukuda, Yoshiko Oshiro, Nobuyoshi Fukumitsu, Masato Abei, Atsushi Kawaguchi, Yasutaka Hayashi, Ayako Ohkawa, Haruko Hashii, Ayae Kanemoto, Takashi Moritake, Eriko Tohno, Koji Tsuboi, Takeji Sakae, Hideyuki Sakurai
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 82, 3, E529, E535, Mar. 2012, [Peer-reviewed]
English, Scientific journal - INVESTIGATION OF THE GEOMETRIC ACCURACY OF PROTON BEAM IRRADIATION IN THE LIVER
Nobuyoshi Fukumitsu, Takayuki Hashimoto, Toshiyuki Okumura, Masashi Mizumoto, Eriko Tohno, Kuniaki Fukuda, Masato Abei, Takeji Sakae, Hideyuki Sakurai
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 82, 2, 826, 833, Feb. 2012, [Peer-reviewed]
English, Scientific journal - Results of Proton Beam Therapy without Concurrent Chemotherapy for Patients with Unresectable Stage III Non-small Cell Lung Cancer
Yoshiko Oshiro, Masashi Mizumoto, Toshiyuki Okumura, Takayuki Hashimoto, Nobuyoshi Fukumitsu, Ayako Ohkawa, Ayae Kanemoto, Haruko Hashii, Toshiki Ohno, Takeji Sakae, Koji Tsuboi, Hideyuki Sakurai
JOURNAL OF THORACIC ONCOLOGY, 7, 2, 370, 375, Feb. 2012, [Peer-reviewed]
English, Scientific journal - Roles and problems of proton beam radiation therapy for the treatment of pediatric cancer
H.,Sakurai, Y.,Oshiro, M.,Mizumoto, T.,Hashimoto, H.,Ishikawa, T.,Okumura, K.,Tsuboi, T.,Sakae, N.,Fukumitsu, R.,Sumazaki
Second International Conference on Real-time Tumor-tracking Radiation Therapy with 4D Molecular Imaging Technique(第2回分子追跡放射線治療国際会議）, 29, Feb. 2012, [Peer-reviewed]
English, International conference proceedings - Influence of secondary neutrons induced by proton radiotherapy for cancer patients with implantable cardioverter defibrillators
Takayuki Hashimoto, Tomonori Isobe, Haruko Hashii, Hiroaki Kumada, Hiroshi Tada, Toshiyuki Okumura, Koji Tsuboi, Takeji Sakae, Kazutaka Aonuma, Hideyuki Sakurai
RADIATION ONCOLOGY, 7, 10, Jan. 2012, [Peer-reviewed]
English, Scientific journal - Nutrition support for head and neck squamous cell carcinoma patients treated with chemoradiotherapy: how often and how long?
Ishiki H, Onozawa Y, Kojima T, Hironaka S, Fukutomi A, Yasui H, Yamazaki K, Taku K, Machida N, Boku N, Hashimoto T, Nishimura T
ISRN oncology, 2012, 274739, 2012, [Peer-reviewed] - Results of Proton Beam Therapy without Concurrent Chemotherapy for Patients with Unresectable Stage III Non-small Cell Lung Cancer
Y.,Oshiro, M.,Mizumoto, T.,Okumura, T.,Hashimoto, N.,Fukumitsu, A.,Ohkawa, A.,Kanemoto, H.,Hashii, T.,Ohno, T.,Sakae, K.,Tsuboi, H.,Sakurai
J Thorac Oncol, 7, 2, 370, 375, Jan. 2012, [Peer-reviewed]
English, Scientific journal, [INTRODUCTION] This study was performed retrospectively to evaluate the outcome of patients with stage III non-small cell lung cancer (NSCLC) after proton beam therapy (PBT) alone.
[METHODS] The subjects were 57 patients with histologically confirmed NSCLC (stage IIIA/IIIB: 24/33) who received PBT without concurrent chemotherapy. The cohort included 32 cases of squamous cell carcinoma, 18 adenocarcinoma, and 7 non-small cell carcinoma. Lymph node metastases were N0 7, N1 5, N2 30, and N3 15. Planned total doses ranged from 50 to 84.5 GyE (median, 74 GyE).
[RESULTS] Planned treatment was completed in 51 patients (89%). At the time of analysis, 20 patients were alive, and the median follow-up periods were 16.2 months for all patients and 22.2 months for survivors. The median overall survival period was 21.3 months (95% confidence interval: 14.2-28.4 months), and the 1- and 2-year overall survival rates were 65.5% (52.9-78.0%) and 39.4% (25.3-53.5%), respectively. Disease progression occurred in 38 patients, and the 1- and 2-year progression-free survival rates were 36.2% (23.1-49.4%) and 24.9% (12.7-37.2%), respectively. Local recurrence was observed in 13 patients, and the 1- and 2- - Proton beam therapy for liver metastasis from breast carcinoma: Five cases reports and a review of the literatures
A.,Kanemoto, H.,Ishikawa, M.,Mizumoto, T.,Okumura, T.,Hashimoto, Y.,Oshiro, N.,Fukumitsu, K.,Tsuboi, T.,Sakae, H.,Sakurai
International Cancer Conference Journal, 1, 4, 210, 214, Jan. 2012, [Peer-reviewed]
English, Scientific journal - 肝細胞癌に対する陽子線治療 ～筑波大学での治療経験～
福田邦明, 奥村敏之, 安部井誠人, 石川仁, 橋本孝之, 石毛和紀, 兵頭一之介, 坪井康次, 櫻井英幸
第48回日本肝癌研究会, 2012, [Peer-reviewed]
Japanese, Research society - Clinical Features of Refractory Radiation Esophageal Ulcer after Proton Beam Therapy and Its Management in a Patient with Esophageal Cancer
Hisakura,Katsuji, Terashima,Hideo, Nagai,Kentaro, Kohno,Keisuke, Tadano,Sosuke, Enomoto,Tsuyoshi, Inagawa,Satoshi, Hashimoto,Takayuki, Sakurai,Hideyuki, Ohkohchi,Nobuhiro
Jpn J Gastroenterol Surg, 45, 12, 1145, 1152, The Japanese Society of Gastroenterological Surgery, 2012
Japanese, Scientific journal, It has been reported that proton beam therapy is an effective treatment method for patients with locally confined esophageal cancer. However, there seems to be serious problems related to post-radiotherapy (RT) esophageal ulcers. We treated 7 patients who developed post-RT esophageal ulcers with the earliest symptom of esophageal stenosis, which was observed 7–17 months (median, 10.0) after completion of RT. Five of the patients had unhealed ulcers leading to lethal events such as perforation or penetration. The mean time between the appearance of the earliest symptom and lethal episode was no more than 2 months (mean, 2.1). The first 3 patients who underwent conservative therapies died from severe complications caused by perforation or penetration of post-RT esophageal ulcers. In the case of 2 consecutive patients, we performed surgical treatment as soon as possible since there were indications of penetration in post-RT developed esophageal ulcers. Therefore, they could be cured by a salvage operation which was subtotal esophagectomy using the stomach for esophageal replacement. Through the above-mentioned experience, we discussed surgical management for esophageal ulcers after - PROTON BEAM THERAPY FOR HEPATOCELLULAR CARCINOMA: A COMPARISON OF THREE TREATMENT PROTOCOLS
Masashi Mizumoto, Toshiyuki Okumura, Takayuki Hashimoto, Kuniaki Fukuda, Yoshiko Oshiro, Nobuyoshi Fukumitsu, Masato Abei, Atsushi Kawaguchi, Yasutaka Hayashi, Ayako Ookawa, Haruko Hashii, Ayae Kanemoto, Takashi Moritake, Eriko Tohno, Koji Tsuboi, Takeji Sakae, Hideyuki Sakurai
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81, 4, 1039, 1045, Nov. 2011, [Peer-reviewed]
English, Scientific journal - HYPERFRACTIONATED CONCOMITANT BOOST PROTON BEAM THERAPY FOR ESOPHAGEAL CARCINOMA
Masashi Mizumoto, Shinji Sugahara, Toshiyuki Okumura, Takayuki Hashimoto, Yoshiko Oshiro, Nobuyoshi Fukumitsu, Akira Nakahara, Hideo Terashima, Koji Tsuboi, Hideyuki Sakurai
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81, 4, E601, E606, Nov. 2011, [Peer-reviewed]
English, Scientific journal - 進行非小細胞肺癌に対する化学放射線療法における正常肺DVH解析 －X線と陽子線の比較－
大野豊然貴, 水本斉志, 大城佳子, 橋本孝之, 金本彩恵, 榮武二, 坪井康次, 奥村敏之, 櫻井英幸
日本放射線腫瘍学会第24回学術大会抄録集, 257, 257, Nov. 2011, [Peer-reviewed]
Japanese, Research society - Radiotherapy for Patients with Symptomatic Intramedullary Spinal Cord Metastasis
Haruko Hashii, Masashi Mizumoto, Ayae Kanemoto, Hideyuki Harada, Hirofumi Asakura, Takayuki Hashimoto, Kazuhisa Furutani, Hirohisa Katagiri, Yoko Nakasu, Tetsuo Nishimura
JOURNAL OF RADIATION RESEARCH, 52, 5, 641, 645, Sep. 2011, [Peer-reviewed]
English, Scientific journal - 乳癌肝転移に対する陽子線治療症例の検討
金本 彩恵, 水本 斉志, 奥村 敏之, 橋本 孝之, 大城 佳子, 福光 延吉, 大川 綾子, 橋井 晴子, 榮 武二, 坪井 康次, 櫻井 英幸
日本乳癌学会総会プログラム抄録集, 19回, 325, 325, (一社)日本乳癌学会, Sep. 2011
Japanese - Occurrence and Clinical Features of Brain Metastasis after Chemoradiotherapy for Esophageal Carcinoma
Ayae Kanemoto, Takayuki Hashimoto, Hideyuki Harada, Hirofumi Asakura, Hirofumi Ogawa, Kazuhisa Furutani, Narikazu Boku, Yoko Nakasu, Tetsuo Nishimura
JOURNAL OF RADIATION RESEARCH, 52, 4, 509, 515, Jul. 2011, [Peer-reviewed]
English, Scientific journal - Efficacy and limitation of radiation therapy for hepatocellular carcinoma complicated with liver cirrhosis
Abei,M, Fukuda,K, Okumura,T, Fukumitsu,N, Hashimoto,T, Mizumoto,M, Ishige,K, Ohkohchi,N, Tsuboi,K, Hyodo,I, Sakurai,H
2nd Asia-Pacific Primary Liver Cancer Expert Meeting. Workshop "Radiotherapy of HCC", Jul. 2011, [Peer-reviewed]
English, International conference proceedings - Displacement of hepatic tumor at time to exposure in end-expiratory-triggered-pulse proton therapy
Yoshiko Oshiro, Toshiyuki Okumura, Masaya Ishida, Shinji Sugahara, Masashi Mizumoto, Takayuki Hashimoto, Kiyoshi Yasuoka, Koji Tsuboi, Takeji Sakae, Hideyuki Sakurai
RADIOTHERAPY AND ONCOLOGY, 99, 2, 124, 130, May 2011, [Peer-reviewed]
English, Scientific journal - Pediatric nasopharyngeal carcinoma treated with proton beam therapy. Two case reports
Yoshiko Oshiro, Shinji Sugahara, Takashi Fukushima, Toshiyuki Okumura, Tomohei Nakao, Masashi Mizumoto, Takayuki Hashimoto, Koji Tsuboi, Michio Kaneko, Hideyuki Sakurai
ACTA ONCOLOGICA, 50, 3, 470, 473, Apr. 2011, [Peer-reviewed]
English - Palliative radiotherapy for bleeding from advanced gastric cancer: is a schedule of 30 Gy in 10 fractions adequate?
Hirofumi Asakura, Takayuki Hashimoto, Hideyuki Harada, Masashi Mizumoto, Kazuhisa Furutani, Noriaki Hasuike, Masaki Matsuoka, Hiroyuki Ono, Narikazu Boku, Tetsuo Nishimura
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 137, 1, 125, 130, Jan. 2011, [Peer-reviewed]
English, Scientific journal - RADIOTHERAPY FOR PATIENTS WITH METASTASES TO THE SPINAL COLUMN: A REVIEW OF 603 PATIENTS AT SHIZUOKA CANCER CENTER HOSPITAL
Masashi Mizumoto, Hideyuki Harada, Hirofumi Asakura, Takayuki Hashimoto, Kazuhisa Furutani, Haruko Hashii, Hideki Murata, Tatsuya Takagi, Hirohisa Katagiri, Mitsuru Takahashi, Tetsuo Nishimura
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 79, 1, 208, 213, Jan. 2011, [Peer-reviewed]
English, Scientific journal - Designed-Seamless Irradiation Technique (D-SLIT) for Extended Whole Mediastinal Proton-Beam Irradiation for Esophageal Cancer
Okonogi, N, Hashimoto, T, Ishida, M, Terunuma, T, Okumura, T, Sakae, T, Sakurai, H
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81, 2::Suppl. S, S313, S313, ELSEVIER SCIENCE INC, Jan. 2011, [Peer-reviewed]
English, Scientific journal - Evaluation of Secondary Neutron Dose in Particle and High Energy X-ray Therapy
Isobe, T, Hashimoto, T, Kumada, H, Hashii, H, Takada, K, Matsufuji, N, Hanmura, M, Fukuda, S, Sakurai, H, Sakae, T
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81, 2::Suppl. S, S875, S876, ELSEVIER SCIENCE INC, Jan. 2011, [Peer-reviewed]
English, International conference proceedings - Application of the multi-modal Monte-Carlo treatment planning system combined with PHITS to proton radiotherapy
Kumada, H, Sakae, T, Saito, K, Isobe, T, Hashimoto, T, Sakurai, H
Progress in Nuclear Science and Technology, 2, 213, 218, Jan. 2011, [Peer-reviewed]
English, Scientific journal - Effects of secondary neutron beam generated in radiotherapy on electronic medical devices．
Isobe,T, Kumada,H, Takada,K, Hashimoto,T, Hashii,H, Shida,K, Tadano,K, Fujibuchi,T, Hanmura,M, Sakurai,H, Sakae,T
Progress in Nuclear Science and Technology, 2, 524, 529, 2011, [Peer-reviewed]
English, Scientific journal - Hyperfractionated Concomitant Boost Proton Radiotherapy for Supratentorial Glioblastoma Multiforme: Analysis of Long Survival Patients
Mizumoto, M, Tsuboi, K, Okumura, T, Hashimoto, T, Oshiro, Y, Fukumitsu, N, Hayashi, Y, Ohkawa, A, Sakae, T, Sakurai, H
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81, 2::Suppl. S, S278, S278, ELSEVIER SCIENCE INC, Jan. 2011, [Peer-reviewed]
English, International conference proceedings - Proton Beam Therapy for Metastatic Liver Cancer
Hashimoto, T, Okumura, T, Kanemoto, A, Hashii, H, Ohkawa, A, Oshiro, Y, Mizumoto, M, Fukumitsu, N, Tsuboi, K, Sakurai, H
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81, 2::Suppl. S, S353, S353, ELSEVIER SCIENCE INC, Jan. 2011, [Peer-reviewed]
English, Scientific journal - Results Of Proton Beams Radiotherapy Without Concurrent Chemotherapy For Patients With Unresectable Stage III Non-small Cell Lung Cancer
Oshiro, Y, Okumura, T, Mizumoto, M, Hashimoto, T, Fukumitsu, N, Ohkawa, A, Kanemoto, A, Hashii, H, Tsuboi, K, Sakurai, H
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81, 2::Suppl. S, S576, S577, ELSEVIER SCIENCE INC, Jan. 2011, [Peer-reviewed]
English, Scientific journal - Influence of Neutron Generated in 10 MV-X-ray Irradiation and Proton Beam on Implatable Cardioverter Defibrillators(ICDs)
Isobe, T, Kumada, H, Hashimoto, T, Hashii, H, Sakurai, H, Sakae, T
The Radiological Society of North America（RSNA）96 t Scientific Assembly and Annual Meeting, Dec. 2010, [Peer-reviewed]
English, International conference proceedings - 肝腫瘍陽子線治療の照射精度の検討
福光延吉, 橋本孝之, 奥村敏之, 橋井晴子, 金本彩恵, 大川綾子, 水本斉志, 榮武二, 坪井康次, 櫻井英幸
日本放射線腫瘍学会第23回学術大会, Nov. 2010, [Peer-reviewed]
Japanese, Research society - A case of large intrahepatic cholangiocarcinoma treated with concurrent proton beam therapy and TS-1
Takayuki Hashimoto
Liver Cancer, 16, 2, 164-170, 癌と化学療法社, Nov. 2010, [Peer-reviewed]
Japanese, Scientific journal - Application of Monte-Carlo treatment planning system “JCDS-FX with PHITS”to proton radiotherapy
Kumada, H, Sakae, T, Saito, K, Isobe, T, Hashimoto, T, Sakurai, H
Joint International Conference on Supercomputiong in Nuclear Applications + Monte Carlo 2010, Oct. 2010, [Peer-reviewed]
English, International conference proceedings - Radiation-induced rib fracture after hypofractionated proton beam therapy for hepatocellular carcinoma
Kanemoto, A, Mizumoto, M, Okumura, T, Moritake, T, Hashimoto, T, Ohshiro, Y Ohkawa, A, Hashii H, Sakae, T, Tsuboi K, Sakurai, H
European Society for Therapeutic Radiology and Oncology(ESTRO 29), Sep. 2010, [Peer-reviewed]
English, International conference proceedings - がんの放射線治療のなかでの陽子線治療の位置付け
櫻井英幸, 奥村敏之, 橋本孝之, 水本斉志, 大城佳子, 大川綾子, 金本彩恵, 橋井晴子, 盛武敬, 坪井康次, 磯辺智範, 照沼利之, 安岡聖, 熊田博明, 榮武二
癌の臨床, 55, 12, 829-846, 836, 篠原出版社, Aug. 2010, [Peer-reviewed]
Japanese, Scientific journal - 肝癌の放射線治療－粒子線治療の立場から-
櫻井英幸, 奥村敏之, 橋本孝之, 水本斉志, 大城佳子, 福光延吉, 盛武敬, 坪井康次, 榮武二
第22回日本高精度放射線外部照射研究会, 31, Jul. 2010, [Peer-reviewed]
Japanese, Research society - 転移性肝癌に対する陽子線治療成績
橋本孝之, 福田邦明, 金本彩恵, 橋井晴子, 大川綾子, 大城佳子, 水本斉志, 森健作, 盛武敬, 安部井誠人, 奥村敏之, 坪井康次, 兵頭一之介, 櫻井英幸
第46回日本肝癌研究会, Jul. 2010, [Peer-reviewed]
Japanese, Research society - 肝内胆管癌に対する陽子線治療の経験
奥村敏之, 安部井誠人, 大川綾子, 正田純一, 福田邦明, 橋本孝之, 水本斉志, 大城佳子, 盛武敬, 森建作, 廣島良規, 金本彩恵, 橋井晴子, 坪井康次, 櫻井英幸
第46回日本肝癌研究会, Jul. 2010, [Peer-reviewed]
Japanese, Research society - Analysis of dose-volume histogram parameters for radiation pneumonitis after definitive concurrent chemoradiotherapy for esophageal cancer
Hirofumi Asakura, Takayuki Hashimoto, Sadamoto Zenda, Hideyuki Harada, Koichi Hirakawa, Masashi Mizumoto, Kazuhisa Furutani, Shuichi Hironaka, Hiroshi Fuji, Shigeyuki Murayama, Narikazu Boku, Tetsuo Nishimura
RADIOTHERAPY AND ONCOLOGY, 95, 2, 240, 244, May 2010, [Peer-reviewed]
English, Scientific journal - Estimation for incidental doses caused by secondary neutrons and photons in proton radiotherapy by Monte-Carlo simulations using PHITS and JCDS.
Kumada, H, Sakae, T, Isobe, T, Hashimoto, T, Terunuma, T, Saito, K
The Third Asian and Oceanic Congress on Radiation Protecrion, May 2010, [Peer-reviewed]
English, International conference proceedings - Estimations for incidental doses caused by secondary neutrons and photons in proton therapy by Monte-Calro simulation with PHITS
Kumada, H, Sakae, T, Terunuma, T, Isobe, T, Hashimoto, T, Saito, K, 櫻井, 英幸
The 49th Particle Therapy Co-Operative Group, 132, May 2010, [Peer-reviewed]
English, International conference proceedings - Radiological Response and Clinical Outcome in Patients with Femoral Bone Metastases after Radiotherapy
Hideyuki Harada, Hirohisa Katagiri, Minoru Kamata, Yasuo Yoshioka, Hirofumi Asakura, Takayuki Hashimoto, Kazuhisa Furutani, Mitsuru Takahashi, Harumi Sakahara, Tetsuo Nishimura
JOURNAL OF RADIATION RESEARCH, 51, 2, 131, 136, Mar. 2010, [Peer-reviewed]
English, Scientific journal - Proton beam therapy for hepatocellular carcinoma
Hideyuki,Sakurai, Toshiyuki,Okumura, Takayuki,Hashimoto, Masashi,Mizumoto, Yoshiko,Ohshiro, Takashi,Moritake, Koji,Tsuboi, Takeji,Sakae
IX Annual International Cancer Confernce(RGCON2010), 128, 129, Mar. 2010, [Peer-reviewed]
English, International conference proceedings - PMRCにおけるパッチ照射接合部の検証法
石田 真也, 榮 武二, 宮本 俊男, 照沼 利之, 佐藤 勝, 橋本 孝之, 藤崎 達也
日本放射線技術学会総会学術大会予稿集, 66回, 286, 286, (公社)日本放射線技術学会, Feb. 2010
Japanese - 肝癌治療における放射線科の現状と未来 粒子線治療の立場から
櫻井 英幸, 奥村 敏之, 橋本 孝之, 水本 斉志, 大城 佳子, 大川 綾子, 金本 彩恵, 橋井 晴子, 盛武 敬, 坪井 康次
日本医学放射線学会学術集会抄録集, 69回, S75, S75, (公社)日本医学放射線学会, Feb. 2010
Japanese - 肝腫瘍に対する陽子線治療後肋骨骨折をきたした５例の検討
金本彩恵, 水本斉志, 橋本孝之, 大城佳子, 大川綾子, 橋井晴子, 盛武敬, 坪井康次, 奥村敏之, 櫻井英幸
第69回日本医学放射線学会総会抄録集, 69回, S364, S364, (公社)日本医学放射線学会, Feb. 2010, [Peer-reviewed]
Japanese, Research society - 肝内胆管癌に対する陽子線治療成績
大川綾子, 橋本孝之, 金本彩恵, 橋井晴子, 大城佳子, 水本斉志, 盛武敬, 奥村敏之, 坪井康次, 櫻井英幸
第69回日本医学放射線学会総会抄録集, 69回, S363-4, S364, (公社)日本医学放射線学会, Feb. 2010, [Peer-reviewed]
Japanese, Research society - Proton beam therapy at PMRC, University of Tsukuba -present and future
Sakurai, H, Okumura, T, Hashimoto, T, Mizumoto, M, Oshiro, Y, Ohkawa, A, Hashii, H, Kanemoto, A, Moritake, T, Tsuboi, K, Terunuma, T, Yasuoka, K, Kumada, H, Sakae, T
Scientific Meeting, PTCOG 49, 7, Jan. 2010, [Peer-reviewed]
English, International conference proceedings - Proton Beam Therapy for Intrahepatic Cholangiocarcinoma
Ohkawa, A, Hashimoto, T, Okumura, T, Abei, M, Fukuda, K, Mizumoto, M, Oshiro, Y, Sakae, T, Tsuboi, K, Sakurai, H
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78, 3::Suppl. S, 0, 0, ELSEVIER SCIENCE INC, Jan. 2010, [Peer-reviewed]
English, Scientific journal - T1-3前立腺癌に対する陽子線治療の成績
宮永直人, 橋本孝之, 菅原信二, 小野澤瑞樹, 水本斉志, 及川剛宏, 宮崎淳, 関戸哲利, 河合弘二, 奥村敏之, 島居徹, 櫻井英幸, 赤座英之
泌尿器外科, 23, 8, 1189, 1192, Jan. 2010, [Peer-reviewed]
Japanese, Scientific journal - Influence of Particle Therapy on Implantable Cardiac Devices: An Experimental Study
Hashimoto, T, Hashii, H, Isobe, T, Ohkawa, A, Yonai, S, Matsufuji, N, Fukuda, S, Sakae, T, Aonuma, K, Sakurai, H
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78, 3::Suppl. S, 0, 0, ELSEVIER SCIENCE INC, Jan. 2010, [Peer-reviewed]
English, Scientific journal - RESIDUAL MOTION AND DUTY TIME IN RESPIRATORY GATING RADIOTHERAPY USING INDIVIDUALIZED OR POPULATION-BASED WINDOWS
Hiroshi Fuji, Yoshihiro Asada, Masumi Numano, Haruo Yamashita, Tetsuo Nishimura, Takayuki Hashimoto, Hideyuki Harada, Hirofumi Asakura, Shigeyuki Murayama
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75, 2, 564, 570, Oct. 2009, [Peer-reviewed]
English, Scientific journal - OPTIMAL TIMING OF ENDOSCOPIC EVALUATION OF THE PRIMARY SITE OF ESOPHAGEAL CANCER AFTER CHEMORADIOTHERAPY OR RADIOTHERAPY: A RETROSPECTIVE ANALYSIS
Sadamoto Zenda, Shuichi Hironaka, Keisei Taku, Hiroshi Sato, Takayuki Hashimoto, Noriaki Hasuike, Narikazu Boku, Yasuhiro Tsubosa, Hiroyuki Ono, Tetsuo Nishimura
DIGESTIVE ENDOSCOPY, 21, 4, 245, 251, Oct. 2009, [Peer-reviewed]
English, Scientific journal - 長径2.5cm以上の脳動静脈奇形に対する陽子線分割照射療法
奥村敏之, 坪井康次, 橋本孝之, 水本斉志, 大城佳子, 林靖孝, 大川綾子, 橋井晴子, 金本彩恵, 櫻井英幸
日本放射線腫瘍学会第22回学術大会, Sep. 2009, [Peer-reviewed]
Japanese, Research society - 頭蓋底脊索腫/軟骨肉腫に対する陽子線照射の治療成績
水本斉志, 奥村敏之, 林靖孝, 橋本孝之, 大城佳子, 大川綾子, 金本彩恵, 橋井晴子, 櫻井英幸, 坪井康次
日本放射線腫瘍学会第22回学術大会, Sep. 2009, [Peer-reviewed]
Japanese, Research society - 進行食道癌に対して化学療法と陽子線治療を併用した3症例
橋井晴子, 奥村敏之, 橋本孝之, 大城佳子, 水本斉志, 盛武敬, 大川綾子, 金本彩恵, 坪井康次, 櫻井英幸
日本放射線腫瘍学会第22回学術大会, Sep. 2009, [Peer-reviewed]
Japanese, Research society - 陽子線治療時に呼吸同期照射を行った肝腫瘍例のPTV marginの検討
金本彩恵, 大城佳子, 奥村敏之, 水本斉志, 橋本孝之, 盛武敬, 大川綾子, 橋井晴子, 坪井康次, 櫻井英幸
日本放射線腫瘍学会第22回学術大会, Sep. 2009, [Peer-reviewed]
Japanese, Research society - The use of image analysis software system to evaluate the geometrical accuracy of proton beam irradiation in the liver
Nobuyoshi,Fukumitsu, Haruko,Hashii, Yoshiko,Ohshiro, Masashi,Mizumoto, Takayuki,Hashimoto, Toshiyuki,Okumura, Takeji,Sakae, Koji,Tsuboi, Hideyuki,Sakurai
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75, 3::Suppl. S, ELSEVIER SCIENCE INC, Jan. 2009, [Peer-reviewed]
English, International conference proceedings - FEASIBILITY OF PROTON BEAM THERAPY FOR PEDIATRIC TUMOR
FUJI Hiroshi, ISHIDA Yuji, MURAYAMA Shigeyuki, YAMASHITA Haruo, HASHIMOTO Takayuki, HARADA Hideyuki, ASAKURA Hirofumi, FURUTANI Kazuhisa, NISHIMURA Tetsuo
The Journal of JASTRO, 20, 4, 143, 149, 25 Dec. 2008
Japanese - Proton beam therapy interference with implanted cardiac pacemakers
Yoshiko Oshiro, Shinji Sugahara, Mio Noma, Masato Sato, Yuzuru Sakakibara, Takeji Sakae, Yasutaka Hayashi, Hidetsugu Nakayama, Koji Tsuboi, Nobuyoshi Fukumitsu, Ayae Kanemoto, Takayuki Hashimoto, Koichi Tokuuye
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72, 3, 723, 727, Nov. 2008, [Peer-reviewed]
English, Scientific journal - Prognostic Factors and a Scoring System for Survival After Radiotherapy for Metastases to the Spinal Column A Review of 544 Patients at Shizuoka Cancer Center Hospital
Masashi Mizumoto, Hideyuki Harada, Hirofumi Asakura, Takayuki Hashimoto, Kazuhisa Furutani, Haruko Hashii, Tatsuya Takagi, Hirohisa Katagiri, Mitsuru Takahashi, Tetsuo Nishimura
CANCER, 113, 10, 2816, 2822, Nov. 2008, [Peer-reviewed]
English, Scientific journal - Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer
Koichi Taira, Narikazu Boku, Akira Fukutomi, Yusuke Onozawa, Shuichi Hironaka, Takayuki Yoshino, Hirofumi Yasui, Kentaro Yamazaki, Keisei Taku, Takayuki Hashimoto, Tetsuo Nishimura
JOURNAL OF GASTROENTEROLOGY, 43, 11, 875, 880, Nov. 2008, [Peer-reviewed]
English, Scientific journal - 食道癌化学放射線療法後の心毒性の検討—dose‐volume histogramを用いた評価—第2報
橋本孝之, 朝倉浩文, 全田貞幹, 金本彩恵, 小川洋史, 原田英幸, 古谷和久, 清水伸一, 白土博樹, 西村哲夫
日本放射線腫よう学会誌, 20, Supplement 1, 164, 22 Sep. 2008
Japanese - Proton beam therapy interference with implanted cardiac pacemakers
Oshiro,Y, Sugahara,S, Noma,M, Sato,M, Sakakibara,Y, Sakae,T, Hayashi,Y, Nakayama,H, Tsuboi,K, Fukumitsu,N, Kanemoto,A, Hashimoto,T, Tokuuye,K
Int J Radiat Oncol Biol Phys, 72, 3, 723, 727, Jan. 2008, [Peer-reviewed], [International Magazine]
English, Scientific journal, [PURPOSE] To investigate the effect of proton beam therapy (PBT) on implanted cardiac pacemaker function.
[METHODS AND MATERIALS] After a phantom study confirmed the safety of PBT in patients with cardiac pacemakers, we treated 8 patients with implanted pacemakers using PBT to a total tumor dose of 33-77 gray equivalents (GyE) in dose fractions of 2.2-6.6 GyE. The combined total number of PBT sessions was 127. Although all pulse generators remained outside the treatment field, 4 patients had pacing leads in the radiation field. All patients were monitored by means of electrocardiogram during treatment, and pacemakers were routinely examined before and after PBT.
[RESULTS] The phantom study showed no effect of neutron scatter on pacemaker generators. In the study, changes in heart rate occurred three times (2.4%) in 2 patients. However, these patients remained completely asymptomatic throughout the PBT course.
[CONCLUSIONS] PBT can result in pacemaker malfunctions that manifest as changes in pulse rate and pulse patterns. Therefore, patients with cardiac pacemakers should be monitored by means of electrocardiogram during PBT. - RADIOTHERAPY FOR PATIENTS WITH MALIGNANT DISEASES AGED 85 YEARS OR OLDER
ASAKURA Hirofumi, MIZUMOTO Masashi, ZENDA Sadamoto, HARADA Hideyuki, HASHIMOTO Takayuki, HIRAKAWA Koichi, NUMANO Masumi, FUJI Hiroshi, MURAYAMA Shigeyuki, NISHIMURA Tetsuo
The Journal of JASTRO, 19, 4, 283, 287, 25 Dec. 2007
Japanese - Classical tandem-source dwelling covering the entire uterus: Essential in modern intracavitary radiotherapy for cervical cancer?
Kiyoshi Ohara, Keiko Nemoto, Kayoko Ohnishi, Takayuki Hashimoto, Nobuyoshi Fukumitsu, Masaharu Hata, Shinji Sugahara, Koichi Tokuuye, Yasuyuki Akine
Radiation Medicine - Medical Imaging and Radiation Oncology, 25, 8, 386, 392, 8, Oct. 2007, [Peer-reviewed]
English, Scientific journal - Proton irradiation in a single fraction for hepatocellular carcinoma patients with uncontrollable ascites
Masaharu Hata, Koichi Tokuuye, Shinji Sugahara, Eriko Tohno, Nobuyoshi Fukumitsu, Takayuki Hashimoto, Kayoko Ohnishi, Keiko Nemoto, Kiyoshi Ohara, Takeji Sakae, Yasuyuki Akine
STRAHLENTHERAPIE UND ONKOLOGIE, 183, 8, 411, 416, Aug. 2007, [Peer-reviewed]
English, Scientific journal - Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: Preliminary results of a phase I/II clinical study
Masaharu Hata, Koichi Tokuuye, Kenji Kagei, Shinji Sugahara, Hidetsugu Nakayama, Nobuyoshi Fukumitsu, Takayuki Hashimoto, Masashi Mizumoto, Kiyoshi Ohara, Yasuyuki Akine
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 68, 3, 786, 793, Jul. 2007, [Peer-reviewed]
English, Scientific journal - Proton beam therapy for hepatocellular carcinoma with inferior vena cava tumor thrombus: Report of three cases
Masashi Mizumoto, Koichi Tokuuye, Shinji Sugahara, Masaharu Hata, Nobuyoshi Fukumitsu, Takayuki Hashimoto, Kayoko Ohnishi, Keiko Nemoto, Kiyoshi Ohara, Yasushi Matsuzaki, Eriko Tohno, Yasuyuki Akine
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 37, 6, 459, 462, Jun. 2007, [Peer-reviewed]
English, Scientific journal - Explanation for the failure of neoadjuvant chemotherapy to improve outcomes after radiotherapy for locally advanced uterine cervical cancer from the standpoint of the tumor regression rate
Kiyoshi Ohara, Hajime Tsunoda, Yumiko Oishi Tanaka, Kayoko Ohnishi, Keiko Nemoto, Takayuki Hashimoto, Nobuyoshi Fukumitsu, Masaharu Hata, Shinji Sugahara, Koichi Tokuuye, Hiroyuki Yoshikawa, Yasuyuki Akine
Radiation Medicine - Medical Imaging and Radiation Oncology, 25, 2, 53, 59, 2, Feb. 2007, [Peer-reviewed]
English, Scientific journal - Sequential evaluation of hepatic functional reserve by (99m)Technetium-galactosyl human serum albumin scinitigraphy after proton beam therapy: a report of three cases and a review of the literatures
Hiroshi Igaki, Koichi Tokuuye, Tohoru Takeda, Shinji Sugahara, Masaharu Hata, Takayuki Hashimoto, Nobuyoshi Fukumitsu, Jin Wu, Kayoko Ohnishi, Kiyoshi Ohara, Yasuyuki Akine
ACTA ONCOLOGICA, 45, 8, 1102, 1107, Dec. 2006, [Peer-reviewed]
English, Scientific journal - A patient surviving for eight years after proton and x-ray irradiation for advanced esophageal cancer
Nobuyoshi Fukumitsu, Koichi Tokuuye, Shinji Sugahara, Takayuki Hashimoto, Masaharu Hata, Kiyoshi Ohara, Takeshi Shibahara, Akira Nakahara, Yasuyuki Akine
ACTA ONCOLOGICA, 45, 8, 1132, 1134, Dec. 2006, [Peer-reviewed]
English - Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis
Masaharu Hata, Koichi Tokuuye, Shinji Sugahara, Nobuyoshi Fukumitsu, Takayuki Hashimoto, Kayoko Ohnishi, Keiko Nemoto, Kiyoshi Ohara, Yasushi Matsuzaki, Yasuyuki Akine
STRAHLENTHERAPIE UND ONKOLOGIE, 182, 12, 713, 720, Dec. 2006, [Peer-reviewed]
English, Scientific journal - Proton beam therapy for hepatocellular carcinoma with limited treatment options
Masaharu Hata, Koichi Tokuuye, Shinji Sugahara, Nobuyoshi Fukumitsu, Takayuki Hashimoto, Kayoko Ohnishi, Keiko Nemoto, Kiyoshi Ohara, Yasushi Matsuzaki, Yasuyuki Akine
CANCER, 107, 3, 591, 598, Aug. 2006, [Peer-reviewed]
English, Scientific journal - Repeated proton beam therapy for hepatocellular carcinoma
T Hashimoto, K Tokuuye, N Fukumitsu, H Igaki, M Hata, K Kagei, S Sugahara, K Ohara, Y Matsuzaki, Y Akine
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 65, 1, 196, 202, May 2006, [Peer-reviewed]
English, Scientific journal - Proton beam therapy for invasive bladder cancer: A prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy
M Hata, N Miyanaga, K Tokuuye, Y Saida, K Ohara, S Sugahara, K Kagei, H Igaki, T Hashimoto, K Hattori, T Shimazu, H Akaza, Y Akine
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 64, 5, 1371, 1379, Apr. 2006, [Peer-reviewed]
English, Scientific journal - Early determination of uterine cervical squamous cell carcinoma radioresponse identifies high- and low-response tumors
K Ohara, A Oki, YO Tanaka, K Onishi, N Fukumitsu, T Hashimoto, T Satoh, H Tsunoda, M Hata, S Sugahara, K Tokuuye, Y Akine, H Yoshikawa
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 64, 4, 1179, 1182, Mar. 2006, [Peer-reviewed]
English, Scientific journal - Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus
M Hata, K Tokuuye, S Sugahara, K Kagei, H Igaki, T Hashimoto, K Ohara, Y Matsuzaki, N Tanaka, Y Akine
CANCER, 104, 4, 794, 801, Aug. 2005, [Peer-reviewed]
English, Scientific journal - Real-time monitoring of a digestive tract marker to reduce adverse effects of moving organs at risk (OAR) in radiotherapy for thoracic and abdominal tumors
T Hashimoto, H Shirato, M Kato, K Yamazaki, N Kurauchi, T Morikawa, S Shimizu, YC Ahn, Y Akine, K Miyasaka
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 61, 5, 1559, 1564, Apr. 2005, [Peer-reviewed]
English, Scientific journal - Clinical results of proton beam therapy for skull base chordoma
H Igaki, K Tokuuye, T Okumura, S Sugahara, K Kagei, M Hata, K Ohara, T Hashimoto, K Tsuboi, S Takano, A Matsumura, Y Akine
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 60, 4, 1120, 1126, Nov. 2004, [Peer-reviewed]
English, Scientific journal - High dose three-dimensional conformal boost (3DCB) using an orthogonal diagnostic X-ray set-up for patients with gynecological malignancy: a new application of real-time tumor-tracking system
R Yamamoto, A Yonesaka, S Nishioka, H Watari, T Hashimoto, D Uchida, H Taguchi, T Nishioka, B Miyasaka, N Sakuragi, H Shirato
RADIOTHERAPY AND ONCOLOGY, 73, 2, 219, 222, Nov. 2004, [Peer-reviewed]
English, Scientific journal - PROTON BEAM THERAPY FOR LARGE HEPATOCELLULAR CARCINOMA
NEMOTO Keiko, TOKUUE Koichi, ONISHI Kayoko, MIZUMOTO Masashi, HASHIMOTO Takayuki, IGAKI Hiroshi, HATA Masaharu, KAGEI Kenji, SUGAHARA Shinji, OHARA Kiyoshi, AKINE Yasuyuki
The Journal of JASTRO, 16, 3, 177, 182, (公社)日本放射線腫瘍学会, 25 Sep. 2004
Japanese - Application of real-time tumor-tracking and gated radiotherapy system for unresectable pancreatic cancer
YC Ahn, S Shimizuz, H Shirato, T Hashimoto, Y Osaka, XQ Zhang, T Abe, M Hosokawa, K Miyasaka
YONSEI MEDICAL JOURNAL, 45, 4, 584, 590, Aug. 2004, [Peer-reviewed]
English, Scientific journal - Initial Experience of Proton Beam Therapy at the New Facility of the University of Tsukuba
Kagei Kenji, Akine Yasuyuki, Ohara Kiyoshi, Hashimoto Takayuki, Igaki Hiroshi, Hata Masaharu, Sugahara Shinji, Tokuuye Koichi
日本医学放射線学会雑誌, 64, 4, 225, 230, 日本医学放射線学会, 25 May 2004
Japanese - Initial experience of proton beam therapy at the new facility of the University of Tsukuba
Kagei Kenji, Tokuuye Koichi, Sugahara Shinji, Hata Masaharu, Igaki Hiroshi, Hashimoto Takayuki, Ohara Kiyoshi, Akine Yasuyuki
Nippon Acta Radiologica, 64, 4, 225, 230, 4, 25 May 2004, [Peer-reviewed]
Japanese, Scientific journal - Proton therapy for head and neck malignancies at Tsukuba
K Tokuuye, Y Akine, K Kagei, M Hata, T Hashimoto, T Mizumoto, Y Ohshiro, S Sugahara, K Ohara, T Okumura, J Kusakari, H Yoshida, F Otsuka
STRAHLENTHERAPIE UND ONKOLOGIE, 180, 2, 96, +, Feb. 2004, [Peer-reviewed]
German, Scientific journal - Real-time monitoring of a digestive-tract marker to reduce adverse effects of moving organs at risk (OAR) in radiotherapy for thoracic and abdominal tumors
T Hashimoto, M Kato, H Shirato, S Shimizu, Y Ahn, N Kurauchi, T Morikawa, K Yamazaki, Y Akine, K Miyasaka
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 60, 1, S414, S414, 2004, [Peer-reviewed]
English - RESULTS OF A SAFETY TEST FOR PROTON BEAM THERAPY EQUIPMENT AT THE PROTON MEDICAL RESEARCH CENTER (PMRC), UNIVERSITY OF TSUKUBA
TOKUUYE Koichi, AKINE Yasuyuki, SHIOYAMA Yoshiyuki, KAGEI Kenji, SUGAHARA Shinji, IGAKI Hiroshi, HATA Masaharu, OHARA Kiyoshi, HASHIMOTO Takayuki
The Journal of JASTRO, 15, 4, 277, 283, Japanese Society for Therapeutic Radiology and Oncology, 25 Dec. 2003
Japanese, A new hospital-based proton radiotherapy facility having two treatment rooms with a rotating gantry each and an experiment room with two horizontal beam ports was built at the Proton Medical Research Center (PMRC), University of Tsukuba. We started proton beam therapy as a clinical study to test the safety of the treatment equipment in September 2001. Six patients, a patient with liver metastases from ovarian carcinoma, two patients with lung carcinoma, a patient with cholangiocarcinoma, a patient with local recurrence of rectal carcinoma and a patient with bone metastasis from breast carcinoma, were enrolled in the study. They were considered unsuitable for other modalities of treatment, and were treated by proton beam therapy alone according to the methods used in the old facility at the University of Tsukuba. They were evaluated with regard to unexpected occurrences due to treatment equipment failures and treatment related toxicities. We observed no occurrence of hazardous events to the patients and no toxicities greater than grade II skin toxicities in the six patients. The results showed that the treatment system was safe and reliable for proton beam therapy. - 動体追跡照射における消化管,胸腹腔への金マーカー挿入術の開発
橋本 孝之, 白土 博樹, 清水 伸一, 大坂 康博, 鬼丸 力也, 藤野 賢治, 宮坂 和男
日本放射線腫瘍学会誌, 15, Suppl.1, 77, 77, (公社)日本放射線腫瘍学会, Oct. 2003
Japanese - Use of small pelvic field instead of whole pelvic field in postoperative radiotherapy for node-negative, high-risk stages I and II cervical squamous cell carcinoma
K Ohara, H Tsunoda, M Nishida, S Sugahara, T Hashimoto, Y Shioyama, K Hasezawa, H Yoshikawa, Y Akine, Y Itai
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 13, 2, 170, 176, Mar. 2003, [Peer-reviewed]
English, Scientific journal - Nonoperative assessment of nodal status for locally advanced cervical squamous cell carcinoma treated by radiotherapy with regard to patterns of treatment failure
K Ohara, YO Tanaka, H Tsunoda, S Sugahara, T Hashimoto, K Kagei, K Tokuuye, Y Akine, H Yoshikawa, Y Itai
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 55, 2, 354, 361, Feb. 2003, [Peer-reviewed]
English, Scientific journal
Other Activities and Achievements
- Comparing predictors of radiation-induced lymphopenia in various timeframes in NSCLC radiotherapy
Takahiro Kanehira, Hiroshi Taguchi, Jun Sakakibara-Konishi, Norio Katoh, Yusuke Uchinami, Keiji Kobashi, Takayuki Hashimoto, Hidefumi Aoyama, RADIOTHERAPY AND ONCOLOGY, 194, S5012, S5015, May 2024
English, Summary international conference - Treatment of intracranial immature teratoma with serum AFP elevation
山口秀, 伊師雪友, 大木聡悟, 茂木洋晃, 長谷河昌孝, 寺下友佳代, 平林真介, 西岡健太郎, 橋本孝之, 真部淳, 藤村幹, 小児の脳神経(Web), 49, 2, 2024 - 前立腺癌に対する超寡分割陽子線治療におけるSFUDとIMPTの比較
田村弘詞, 孫田惠一, 中里慧二, 松尾勇斗, 高尾聖心, 橋本孝之, 青山英史, 北海道放射線技術雑誌(Web), 95, 2023 - 適応陽子線治療における日々の線量分布の迅速評価システムの開発
小橋啓司, 小橋啓司, 西岡健太郎, 西岡健太郎, 橋本孝之, 橋本孝之, 田村弘詞, 中里慧二, 田口大志, 安田耕一, 安田耕一, 打浪雄介, 打浪雄介, 加藤徳雄, 加藤徳雄, 青山英史, 青山英史, 日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集, 36th, 2023 - 免疫チェックポイント阻害薬と放射線治療—Clinical evidences for the combination of immune checkpoint inhibitor and radiation therapy—特集 がん免疫療法の展望 : 免疫チェックポイント阻害薬の併用療法に中心に ; 免疫チェックポイント阻害薬の併用療法のエビデンス
安田 耕一, 志藤 元泰, 小泉 富基, 高橋 周平, 藤田 祥博, 大塚 愛美, 宮﨑 智彦, 西川 昇, 打浪 雄介, 森 崇, 西岡 健太郎, 木下 留美子, 田口 大志, 加藤 徳雄, 橋本 孝之, 青山 英史, 腫瘍内科 = Clinical oncology / 腫瘍内科編集委員会 編, 30, 1, 23, 28, Jul. 2022
Japanese - Treatment Outcome of Definitive Radiotherapy for Cervical Cancer
KINOSHITA Rumiko, UCHINAMI Yusuke, KOIZUMI Fuki, NISHIOKA Kentaro, HASHIMOTO Takayuki, KATO Fumi, MITAMURA Takashi, ITO Yoichi M, MATSUNO Yoshihiro, AOYAMA Hidefumi, 日本医学放射線学会総会抄録集, 81st, 2022 - Evaluation of Visualizing the Prostatic Urinary Tract in MRI With a Super Resolution Deep Learning Model for Urethra Sparing Radiotherapy
T. Yoshimura, K. Nishioka, T. Hashimoto, S. Kogame, K. Seki, H. Sugimori, H. Yamashina, F. Kato, H. Aoyama, K. Kudo, S. Shimizu, International Journal of Radiation Oncology*Biology*Physics, 111, 3, e121, e122, Nov. 2021, [Peer-reviewed]
Elsevier BV, English - Proton beam therapy for reirradiation in pediatric cancer
橋本孝之, 森崇, 西岡健太郎, 打浪雄介, 安田耕一, 木下留美子, 田口大志, 加藤徳雄, 清水伸一, 青山英史, 日本小児血液・がん学会雑誌(Web), 58, 2, 2021 - 陽子線治療—Proton therapy for prostate cancer—特集 前立腺癌診療update : 最新の診断と治療 ; 診断と治療
清水 伸一, 西岡 健太郎, 橋本 孝之, 日本臨床 = Japanese journal of clinical medicine, 78, 6, 977, 982, Jun. 2020
日本臨床社, Japanese - 前立腺がんの陽子線治療—Proton therapy for prostate cancer—特集 泌尿器がんの新しい放射線治療戦略 ; 前立腺がん
清水 伸一, 橋本 孝之, 西岡 健太郎, 泌尿器科 = Urology / 泌尿器科編集委員会 編, 11, 4, 386, 391, Apr. 2020
科学評論社, Japanese - 画像誘導陽子線治療の将来展望
田口大志, 橋本孝之, 橋本孝之, 加藤徳雄, 木下留美子, 安田耕一, 西岡健太郎, 西岡健太郎, 森崇, 打浪雄介, 宮本直樹, 高尾聖心, 清水伸一, 清水伸一, 青山英史, 日本癌治療学会学術集会(Web), 58th, 2020 - 筋層浸潤性膀胱癌に対する膀胱温存治療後患者のHealth-related quality of life
大澤崇宏, 安部崇重, 西岡健太郎, 菊地央, 松本隆児, 橋本孝之, 清水伸一, 青山英史, 村井祥代, 篠原信雄, 日本泌尿器内視鏡学会(Web), 34th, 2020 - 頭蓋内胚細胞腫瘍における放射線化学療法後のsalvage surgeryに関する病理所見からの検討
山口 秀, 茂木 洋晃, 伊師 雪友, 岡本 迪成, 井口 晶裕, 長 祐子, 杉山 未奈子, 橋本 孝之, 岡田 宏美, 寳金 清博, Brain Tumor Pathology, 36, Suppl., 096, 096, May 2019
日本脳腫瘍病理学会, Japanese - ヒステリーや発達障害と評価され診断が遅れた頭蓋内胚細胞腫瘍の2例
本田譲, 原和也, 寺下友佳代, 杉山未奈子, 長祐子, 井口晶裕, 山口健史, 中村明枝, 真部淳, 岡本迪成, 伊師雪友, 茂木洋晃, 山口秀, 森崇, 橋本孝之, 鬼丸力也, 平松泰好, 植竹公明, 佐藤正夫, 日本小児科学会雑誌, 123, 11, 2019 - 全脳全脊髄強度変調陽子線照射が骨髄抑制軽減に有用であったAYA世代胚細胞腫瘍の2例
橋本孝之, 井口晶裕, 寺坂俊介, 杉山未奈子, 山口秀, 小林浩之, 長祐子, 鬼丸力也, 清水伸一, 白土博樹, 日本小児科学会雑誌, 122, 7, 1240, 1240, 01 Jul. 2018
(公社)日本小児科学会, Japanese - 全脳全脊髄強度変調陽子線照射(IMPT)が骨髄抑制軽減に有用であったAYA世代胚細胞腫瘍の2例
橋本 孝之, 寺坂 俊介, 井口 晶裕, 山口 秀, 小林 浩之, 杉山 未奈子, 長 祐子, 森 崇, 高尾 聖心, 松浦 妙子, 鬼丸 力也, 清水 伸一, 白土 博樹, 日本小児血液・がん学会雑誌, 55, 1, 76, 76, Jun. 2018
(一社)日本小児血液・がん学会, Japanese - 全脳全脊髄照射におけるスポットスキャニング陽子線治療とIMRTによる誘発二次発がん率の比較
鈴木俊介, 田村昌也, 鈴木隆介, 高尾聖心, 橋本孝之, 清水伸一, 白土博樹, 日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集, 31st (CD-ROM), 2018 - リンパ脈管筋腫症(LAM)を合併した乳癌に対し乳房温存術後に術後照射を施行した2例
木下留美子, 長江伸樹, 西岡健太郎, 橋本孝之, 清水伸一, 白土博樹, 加藤扶美, 石田直子, 山下啓子, 清水薫子, 鈴木雅, 今野哲, 北海道外科雑誌, 63, 2, 2018 - Prostate position deviation analysis using real-time-image gated spot-scanning proton therapy (RGPT) system for prostate cancer
TAMURA Hiroshi, TAMURA Hiroshi, SHIMIZU Shinichi, NISHIOKA Kentaro, HASHIMOTO Takayuki, YOSHIMURA Takaaki, MATSUO Yuto, MATSUURA Taeko, MATSUURA Taeko, TAKAO Seishin, UMEGAKI Kikuo, UMEGAKI Kikuo, SHIRATO Hiroki, 医学物理 Supplement, 38, 1, 2018 - Benefits of Craniospinal Intensity-modulated Proton Beam Therapy in Reducing the Myelosuppression for Adolescent Germ Cell Tumors: Two Case Reports
Takayuki Hashimoto, Syunsuke Terasaka, Akihiro Iguchi, Shigeru Yamaguchi, Hiroyuki Kobayashi, Minako Sugiyama, Yuko Cho, Takashi Mori, Seishin Takao, Taeko Matsuura, Rikiya Onimaru, Shinichi Shimizu, Hiroki Shirato, PEDIATRIC BLOOD & CANCER, 64, S87, S88, Nov. 2017
English, Summary international conference - An Organ Motion and Acute Toxicity Study of Image-Guided Spot-Scanning Proton Beam Therapy With An Internal Fiducial Marker for Pancreatic Cancers.
Y. Uchinami, N. Katoh, D. Abo, K. Harada, Y. Nishikawa, T. Inoue, T. Hashimoto, R. Onimaru, N. Miyamoto, Y. Sakuhara, S. Shimizu, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 99, 2, E194, E194, Oct. 2017
English, Summary international conference - Analysis of Threshold Doses for Radiation Induced Liver Parenchymal Changes on MRI after Real TimeeImage Gated Spot-Scanning Proton Beam Therapy of Hepatocellular Carcinomas
N. Katoh, Y. Uchinami, S. Takao, K. Yasuda, K. Harada, T. Inoue, T. Matsuura, T. Hashimoto, S. Shimizu, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 99, 2, E159, E160, Oct. 2017
English, Summary international conference - Kasabach-Merritt症候群を合併した血管腫に対する陽子線治療の有用性について
渡邊 敏史, 井口 晶裕, 長 祐子, 杉山 未奈子, 廣瀬 文, 森 崇, 高尾 聖心, 橋本 孝之, 鬼丸 力也, 清水 伸一, 白土 博樹, 日本小児血液・がん学会雑誌, 54, 4, 347, 347, Oct. 2017
(一社)日本小児血液・がん学会, Japanese - Targeting integrins with RGD-conjugated gold nanoparticles in radiotherapy decreases the invasive activity of breast cancer cells
Ping Hsiu Wu, Yasuhito Onodera, Yuki Ichikawa, Yuki Ichikawa, Erinn B. Rankin, Amato J. Giaccia, Yuko Watanabe, Wei Qian, Takayuki Hashimoto, Hiroki Shirato, Hiroki Shirato, Hiroki Shirato, Jin Min Nam, Jin Min Nam, Jin Min Nam, International Journal of Nanomedicine, 12, 5069, 5085, 14 Jul. 2017 - Analysis of inter- and intra fractional partial bladder wall movement using implanted fiducial markers
Kentaro Nishioka, Shinichi Shimizu, Nobuo Shinohara, Yoichi M. Ito, Takashige Abe, Satoru Maruyama, Norio Katoh, Rumiko Kinoshita, Takayuki Hashimoto, Naoki Miyamoto, Rikiya Onimaru, Hiroki Shirato, RADIATION ONCOLOGY, 12, Mar. 2017
English - Analysis of Durations and Dose Rates for Treatment of Moving Liver Tumors Using Real-Time Image Gated Spot Scanning Proton Beam Therapy
S. Shimizu, N. Katoh, T. Hashimoto, K. Nishioka, T. Yoshimura, S. Takao, T. Matsuura, N. Miyamoto, K. Umegaki, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 96, 2, S211, S212, Oct. 2016
English, Summary international conference - Gold Nanoparticles With RGD Peptide in Radiation Therapy Suppress the Invasion Activity of Breast Cancer Cells
P. H. Wu, Y. Onodera, Y. Ichikawa, Y. Watanabe, W. Qian, T. Hashimoto, H. Shirato, J. M. Nam, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 96, 2, E574, E574, Oct. 2016
English, Summary international conference - Radiation Dose to Internal Mammary Lymph Node in Standard Tangential Breast Irradiation
R. Kinoshita, S. Shimizu, Y. Nishikawa, K. Nishioka, T. Hashimoto, R. Suzuki, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 96, 2, E17, E18, Oct. 2016
English, Summary international conference - Spatial distributions of dose enhancement around a gold nanoparticle at several depths of proton Bragg peak
Jihun Kwon, Kenneth Sutherland, Takayuki Hashimoto, Hiroki Shirato, Hiroyuki Date, Nuclear Instruments and Methods in Physics Research, Section B: Beam Interactions with Materials and Atoms, 384, 113, 120, 01 Oct. 2016 - Treatment Time and Dose Rate Analysis for Respiratory Moving Liver Tumor Using Real-time-image Gated Spot Scanning Proton Beam Therapy System
SHIMIZU Shinichi, KATOH Norio, TAKAO Seishin, MATSUURA Taeko, MIYAMOTO Naoki, HASHIMOTO Takayuki, NISHIOKA Kentaro, YOSHIMURA Takaaki, UMEGAKI Kikuo, SHIRATO Hiroki, 日本医学放射線学会総会抄録集, 75th, S225, S225, 29 Feb. 2016
(公社)日本医学放射線学会, English - Particle Therapy Using Protons or Carbon Ions for Cancer Patients With Cardiac Implantable Electronic Devices (CIEDs): A Retrospective Japan Radiological Society Multi-institutional Study
T. Hashimoto, Y. Demizu, T. Isobe, H. Numajiri, S. Fukuda, M. Wakatsuki, H. Yamashita, S. Murayama, S. Takamatsu, H. Katoh, K. Murata, R. Kohno, T. Arimura, T. Matsuura, Y. M. Ito, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 93, 3, E563, E564, Nov. 2015
English, Summary international conference - Development of a Real-Time Image Gated Proton Beam Therapy (RGPT) System and Its Initial Clinical Application to Respiratory Moving Liver Tumors
S. Shimizu, N. Katoh, S. Takao, T. Matsuura, N. Miyamoto, T. Hashimoto, K. Nishioka, T. Yoshimura, Y. Matsuzaki, R. Kinoshita, Y. Nishikawa, R. Onimaru, K. Umegaki, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 93, 3, S42, S42, Nov. 2015
English, Summary international conference - The invasion activity after radiation treatment is suppressed by RGD peptide conjugated gold nanoparticles in breast cancer cells
P. Wu, Y. Onodera, Y. Ichikawa, Y. Watanabe, W. Qian, T. Hashimoto, H. Shirato, J. Nam, MOLECULAR BIOLOGY OF THE CELL, 26, 2015
English, Summary international conference - キャンサーボードが機能した1症例
遠藤将吾, 寺坂俊介, 小林浩之, 山口秀, 茂木洋晃, 金子貞洋, 井口晶裕, 長祐子, 大島淳二郎, 寺坂友佳代, 杉山未奈子, 橋本孝之, 鬼丸力也, 清水伸一, 有賀正, 白戸博樹, 寳金清博, 日本小児血液・がん学会雑誌(Web), 52, 3, 2015 - 食道癌に対する化学放射線療法の有害事象 X線と陽子線の比較
牧島 弘和, 石川 仁, 橋本 孝之, 大野 豊然貴, 菅原 香織, 奥村 敏之, 櫻井 英幸, 日本食道学会学術集会プログラム・抄録集, 68回, 59, 59, Jul. 2014
(NPO)日本食道学会, Japanese - 食道がん治療戦略のUp to Date 食道癌の化学放射線療法と陽子線治療の役割
石川 仁, 奥村 敏之, 水本 斉志, 大西 かよ子, 菅原 香織, 牧島 弘和, 大野 豊然貴, 森脇 俊和, 兵頭 一之介, 久倉 勝治, 田村 孝史, 寺島 秀人, 大河内 信弘, 橋本 孝之, 櫻井 英幸, 日本癌治療学会誌, 49, 3, 770, 770, Jun. 2014
(一社)日本癌治療学会, Japanese - 前立腺放射線治療における膀胱容量の再現性
布施拓, 石川仁, 石川仁, 石田真也, 宮本俊男, 佐藤勝, 橋本孝之, 橋本孝之, 櫻井英幸, 櫻井英幸, 日本放射線技術学会総会学術大会予稿集, 69th, 2013 - 原発性肝癌の陽子線治療
奧村敏之, 橋本孝之, 福田邦明, 安部井誠人, 福光延吉, 水本斉志, 沼尻晴子, 大西かよ子, 石川仁, 坪井康次, 福永潔, 大河内信弘, 櫻井英幸, 日本癌治療学会学術集会(CD-ROM), 51st, ROMBUNNO.OS24-4, 2013
Japanese - ３．SLIT法を用いた食道癌同時併用化学陽子線治療の初期成績
小此木 範之, 橋本 孝之, 榮 武二, 石田 真也, 奥村 敏之, 櫻井 英幸, The Kitakanto medical journal, 62, 2, 225, 225, 01 May 2012
北関東医学会, Japanese - 肝がんの陽子線治療
奥村敏之, 橋本孝之, 福光延吉, 水本斉志, 福永潔, 佐々木亮孝, 盛武敬, 榮武二, 坪井康次, 大河内信弘, 櫻井英幸, 日本外科系連合学会誌, 36, 3, 341, 30 May 2011
Japanese - Radiotherapy Today 2011 放射線治療最前線 高精度放射線治療の適応と成果,そして課題 II)高精度放射線治療の適応と課題:疾患別の検討 6.肝がんの最新放射線治療 粒子線治療―陽子線治療の適応と課題を中心に
奥村敏之, 橋本孝之, 福光延吉, 水本斉志, 大城佳子, 大川綾子, 金本彩恵, 橋井晴子, 大野豊然貴, 小此木範之, 榮武二, 坪井康次, 櫻井英幸, Innervision, 26, 3, 65, 67, 25 Feb. 2011
(株)インナービジョン, Japanese - 肝細胞癌の術後巨大肝内再発に対し,血管内治療と陽子線治療による集学的治療を行った1例
奥村敏之, 安部井誠人, 森健作, 金本彩恵, 福田邦明, 阿部孝志, 橋本孝之, 水本斉志, 大城佳子, 福光延吉, 大川綾子, 橋井晴子, 盛武敬, 榮武二, 坪井康次, 櫻井英幸, Liver Cancer, 16, 2, 155, 161, 19 Nov. 2010
(株)アークメディア, Japanese - 3種類の治療プロトコールを用いた肝細胞癌に対する陽子線治療
水本斉志, 奥村敏之, 橋本孝之, 福田邦明, 大城佳子, 福光延吉, 安部井誠人, 大川綾子, 金本彩恵, 橋井晴子, 盛武敬, 東野英利子, 坪井康次, 栄武二, 櫻井英幸, 日本癌治療学会誌, 45, 2, 589, 589, 21 Sep. 2010
(一社)日本癌治療学会, Japanese - Roles of proton beam therapy as a cancer radiotherapy
櫻井 英幸, 奥村 敏之, 橋本 孝之, Japanese journal of cancer clinics, 55, 12, 829, 836, Dec. 2009
篠原出版新社, Japanese - Cardiac toxicities after concurrent chemoradiotherapy for esophageal cancer - Dose-volume histogram (DVH) analysis
T. Hashimoto, H. Asakura, S. Zenda, H. Hashii, M. Mizumoto, H. Harada, K. Furutani, H. Fuji, S. Murayama, T. Nishimura, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72, 1, S130, S130, 2008
English, Summary international conference - Prognostic impact of total tumor volume in stage III non-small-cell lung cancer treated with concurrent chemoradiotherapy
Harada Hideyuki, Nobuyuki Yamamoto, Toshiaki Takahashi, Hirfumi Asakura, Takayuki Hashimoto, Koichi Hirakawa, Masashi Mizumoto, Hiroshi Fuji, Shigeyuki Murayama, Tetsuo Nisimura, JOURNAL OF THORACIC ONCOLOGY, 2, 8, S450, S450, Aug. 2007
English, Summary international conference - Analysis of dose-volume histogram parameters for radiation pneumonitis after concurrent chemoradiotherapy for esophageal cancer
H. Asakura, T. Hashimoto, S. Zenda, H. Harada, K. Hirakawa, M. Mizumoto, H. Yamashita, H. Fuji, S. Murayama, T. Nishimura, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69, 3, S302, S302, 2007
English, Summary international conference - I期の非小細胞肺癌に対する少分割陽子線治療の初期成績
幡多政治, 徳植公一, 菅原信二, 影井兼司, 中山秀次, 福光延吉, 橋本孝之, 水本斉志, 大原潔, 秋根康之, 日本放射線腫よう学会誌, 18, Supplement 1, 162, 25 Oct. 2006
Japanese - Conventional source dwelling up to the uterine fundus may not be mandatory in intracavitary radiotherapy for cervical cancer
K. Ohara, K. Ohnishi, K. Nemoto, T. Hashimoto, N. Fukumitsu, M. Hata, S. Sugahara, K. Tokuuye, Y. Akine, RADIOTHERAPY AND ONCOLOGY, 81, S254, S254, Oct. 2006
English, Summary international conference - Clinical results of proton beam therapy for locoregionally advanced esophageal cancer
S. Sugahara, K. Tokuuye, A. Nakahara, M. Hata, H. Terashima, N. Fukumitsu, T. Shibahara, H. Nakayama, T. Hashimoto, K. Ohara, Y. Akine, RADIOTHERAPY AND ONCOLOGY, 81, S358, S358, Oct. 2006
English, Summary international conference - 5.肺・胸膜・肝内転移を繰り返し,腎障害・心筋障害も来たした,2002年登録肝芽腫難治症例における治療経過(続報) : CPT-11,陽子線照射,ラジオ波焼灼(RFA)の効果(日本小児肝癌スタディグループ研究会2006,研究会)
平井 みさ子, 金子 道夫, 堀 哲夫, 小室 広昭, 瓜田 泰久, 渡邊 美穂, 星野 論子, 福島 敬, 高橋 実穂, 松枝 清, 橋本 孝之, 小児がん : 小児悪性腫瘍研究会記録, 43, 2, 258, 258, 30 Sep. 2006
日本小児がん学会, Japanese - 限局性前立腺癌に対する陽子線治療
宮永直人, 赤座英之, 及川剛宏, 関戸哲利, 樋之津史郎, 河合弘二, 島居徹, 幡多政治, 徳植公一, 橋本孝之, 福光延吉, 菅原信二, 秋根康之, 泌尿器外科, 19, 8, 951, 954, 15 Aug. 2006
Japanese - 消化管に近接した肝細胞癌に対する陽子線治療の初期成績
徳植公一, 橋本孝之, 福光延吉, 幡多政治, 菅原信二, 根本景子, 大西かよ子, 大原潔, 秋根康之, 日本医学放射線学会学術集会抄録集, 65th, S217, 25 Feb. 2006
Japanese - 合併症により治療法が制限された肝細胞癌患者に対する陽子線治療
幡多政治, 徳植公一, 菅原信二, 福光延吉, 橋本孝之, 大西かよ子, 根本景子, 大原潔, 秋根康之, 日本医学放射線学会学術集会抄録集, 65th, S315, 25 Feb. 2006
Japanese - 子宮頚癌治療におけるネオアジュバント化学療法併用が放射線単独治療に比べ有効でなかった理由
大原潔, 田中優美子, 大西かよ子, 根本景子, 橋本孝之, 福光延吉, 菅原信二, 幡多政治, 徳植公一, 秋根康之, 日本医学放射線学会学術集会抄録集, 65th, S312, 25 Feb. 2006
Japanese - 消化器がんに対する放射線治療 2 各論 (4) 消化器がんに対する陽子線治療
秋根康之, 徳植公一, 菅原信二, 幡多政治, 福光延吉, 橋本孝之, 臨床消化器内科, 21, 3, 315, 322, 20 Feb. 2006
Japanese - Preliminary results of hypofractionated proton beam therapy for hepatocellular carcinoma
N. Fukumitsu, K. Tokuuye, T. Hashimoto, S. Sugahara, M. Hata, K. Ohara, E. Tohno, Y. Akine, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66, 3, S279, S280, 2006
English, Summary international conference - Repeated proton beam therapy for previously irradiated hepatocellular carcinoma - Dose-volume histogram (DVH) analysis
T. Hashimoto, K. Tokuuye, K. Ohnishi, N. Fukumitsu, M. Hata, S. Sugahara, K. Ohara, E. Tohno, T. Nishimura, Y. Akine, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66, 3, S303, S303, 2006
English, Summary international conference - 陽子線治療により視神経が温存された横紋筋肉腫の1例
根本景子, 菅原信二, 徳植公一, 奥村敏之, 影井兼司, 幡多政治, 井垣浩, 大原潔, 橋本孝之, 福光延吉, 秋根康之, 茨城県臨床医学雑誌, 41, 33, 01 Dec. 2005
Japanese - 門脈腫よう栓を伴う肝細胞癌に対する陽子線治療の初期成績
大西かよ子, 幡多政治, 徳植公一, 根本景子, 橋本孝之, 福光延吉, 影井兼司, 菅原信二, 大原潔, 秋根康之, 日本放射線腫よう学会誌, 17, Supplement 1, 89, 25 Oct. 2005
Japanese - ペースメーカー装着患者に対する陽子線治療経験
橋本孝之, 野間美緒, 徳植公一, 福光延吉, 幡多政治, 影井兼司, 菅原信二, 大原潔, 榊原謙, 秋根康之, 日本放射線腫よう学会誌, 17, Supplement 1, 168, 25 Oct. 2005
Japanese - 巨大肝細胞癌に対する陽子線治療成績
根本景子, 徳植公一, 大西かよ子, 橋本孝之, 福光延吉, 幡多正治, 影井兼司, 菅原信二, 大原潔, 秋根康之, 日本放射線腫よう学会誌, 17, Supplement 1, 90, 25 Oct. 2005
Japanese - 重症肝硬変症をともなう肝細胞癌患者に対する陽子線治療
幡多政治, 徳植公一, 菅原信二, 影井兼司, 福光延吉, 橋本孝之, 大西かよ子, 根本景子, 大原潔, 秋根康之, 日本放射線腫よう学会誌, 17, Supplement 1, 106, 25 Oct. 2005
Japanese - Preliminary results of hypofractionated proton beam therapy for hepatocellular carcinoma
N. Fukumitsu, K. Tokuuye, T. Hashimoto, S. Sugahara, K. Kagei, M. Hata, K. Ohara, Y. Akine, EJC SUPPLEMENTS, 3, 2, 206, 206, Oct. 2005
English, Summary international conference - Preliminary results of proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus
K. Ohnishi, M. Hata, K. Tokuuye, K. Nemoto, T. Hashimoto, N. Fukumitsu, S. Sugahara, K. Ohara, Y. Matsuzaki, Y. Akine, EJC SUPPLEMENTS, 3, 2, 223, 223, Oct. 2005
English, Summary international conference - Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis
M. Hata, K. Tokuuye, S. Sugahara, K. Kagei, N. Fukumitsu, T. Hashimoto, K. Ohnishi, K. Ohara, Y. Matsuzaki, Y. Akine, EJC SUPPLEMENTS, 3, 2, 224, 225, Oct. 2005
English, Summary international conference - Dose-response relationship of proton beam therapy for hepatocellular carcinoma
K. Tokuuye, Y. Akine, T. Hashimoto, Y. Fukumitsu, S. Hata, S. Sugahara, K. Ohara, K. Ohnishi, K. Nemoto, Y. Matsuzaki, EJC SUPPLEMENTS, 3, 2, 223, 223, Oct. 2005
English, Summary international conference - 肝細胞癌に対する陽子線単独治療の治療成績
徳植公一, 橋本孝之, 井垣浩, 幡多政治, 影井兼司, 菅原信二, 大城佳子, 福光延吉, 大原潔, 日本医学放射線学会学術集会抄録集, 64th, S160, 25 Feb. 2005
Japanese - 99mTc‐GSAによる肝腫よう陽子線治療後の肝予備能の経時的評価
井垣浩, 徳植公一, 菅原信二, 影井兼司, 幡多政治, 武田徹, 福光延吉, 橋本孝之, 大原潔, 日本医学放射線学会学術集会抄録集, 64th, S180, 25 Feb. 2005
Japanese - Clinical results of proton beam therapy for esophageal cancer at the University of Tsukuba
S Sugahara, K Tokuuye, A Nakahara, H Igaki, M Hata, K Kagei, H Terashima, T Hashimoto, N Fukumitsu, T Shibahara, K Ohara, Y Akine, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 63, 2, S163, S164, 2005
English, Summary international conference - Repeated proton beam therapy for hepatocellular carcinoma
T Hashimoto, K Tokuuye, K Nemoto, K Onishi, N Fukumitsu, H Igaki, M Hata, K Kagei, S Sugahara, K Ohara, Y Matsuzaki, Y Akine, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 63, 2, S159, S160, 2005
English, Summary international conference - Clinical results of proton beam therapy for skull base chordoma
H Iqaki, K Tokuuye, T Okumura, S Sugahara, K Kagei, M Hata, K Ohara, K Tsuboi, T Hashimoto, Y Akine, RADIOTHERAPY AND ONCOLOGY, 73, S258, S258, Oct. 2004
English, Summary international conference - Objective assessment of cervical cancer radioresponse by serum squamous cell carcinoma antigen and magnetic resonance imaging
K Ohara, S Sugahara, K Kagei, M Hata, H Igaki, T Hashimoto, K Tokuuye, Y Akine, RADIOTHERAPY AND ONCOLOGY, 73, S291, S291, Oct. 2004
English, Summary international conference - Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus
M Hata, K Tokuuye, K Ohara, S Sugahara, K Kagei, H Igaki, T Hashimoto, Y Matsuzaki, N Tanaka, Y Akine, RADIOTHERAPY AND ONCOLOGY, 73, S318, S318, Oct. 2004
English, Summary international conference - 神経膠腫に対する陽子線治療成績
井垣 浩, 徳植 公一, 坪井 康次, 菅原 信二, 影井 兼司, 幡多 政治, 橋本 孝之, 大原 潔, 秋根 康之, 日本放射線腫瘍学会誌, 16, Suppl.1, 128, 128, Oct. 2004
(公社)日本放射線腫瘍学会, Japanese - 肝細胞癌の下大静脈腫瘍栓に対する陽子線治療
水本 斉志, 徳植 公一, 橋本 孝之, 幡多 政治, 影井 兼司, 井垣 浩, 菅原 信二, 大原 潔, 秋根 康之, 日本放射線腫瘍学会誌, 16, Suppl.1, 171, 171, Oct. 2004
(公社)日本放射線腫瘍学会, Japanese - 門脈腫瘍栓をともなう肝細胞癌に対する陽子線治療
幡多 政治, 徳植 公一, 菅原 信二, 影井 兼司, 井垣 浩, 橋本 孝之, 水本 斉志, 大原 潔, 秋根 康之, 日本放射線腫瘍学会誌, 16, Suppl.1, 171, 171, Oct. 2004
(公社)日本放射線腫瘍学会, Japanese - 肝細胞癌の放射線治療計画における臨床標的体積の治療医間でのばらつきの検討
橋本 孝之, 徳植 公一, 水本 斉志, 井垣 浩, 幡多 政治, 影井 兼司, 菅原 信二, 大原 潔, 秋根 康之, 日本放射線腫瘍学会誌, 16, Suppl.1, 171, 171, Oct. 2004
(公社)日本放射線腫瘍学会, Japanese - 血清SCC抗原による子宮頸癌の放射線反応評価 MR画像による評価との比較
大原 潔, 橋本 孝之, 影井 兼司, 幡多 政治, 井垣 浩, 菅原 信二, 水本 斉志, 徳植 公一, 秋根 康之, 日本放射線腫瘍学会誌, 16, Suppl.1, 180, 180, Oct. 2004
(公社)日本放射線腫瘍学会, Japanese - 金マーカーの埋め込みを上部消化管内視鏡下に行ったReal-time Tumor Tracking Radiotherapy
森 康明, 小野 雄司, 桂田 武彦, 小野 尚子, 山本 純司, 中川 学, 三浦 洋輔, 工藤 真弓, 結城 敏志, 武居 正明, 宮下 憲暢, 小松 嘉人, 浅香 正博, 中川 宗一, 清水 勇一, 加藤 元嗣, 橋本 孝之, 白土 博樹, Gastroenterological Endoscopy, 46, Suppl.2, 1895, 1895, Sep. 2004
(一社)日本消化器内視鏡学会, Japanese - Initial experience of proton beam therapy at the new facility of the University of Tsukuba
Kagei Kenji, Tokuuye Koichi, Sugahara Shinji, Hata Masaharu, Igaki Hiroshi, Hashimoto Takayuki, Ohara Kiyoshi, Akine Yasuyuki, Nippon Acta Radiologica, 64, 4, 225, 230, 25 May 2004
Japanese
Research Themes
- MR画像誘導陽子線治療システムおよび磁場下の治療計画・検証技法に関する基盤開発
科学研究費助成事業
01 Apr. 2024 - 31 Mar. 2028
松浦 妙子, 宮本 直樹, 打浪 雄介, 高尾 聖心, 陳 叶, 橋本 孝之, 栗山 靖敏, 加藤 徳雄
日本学術振興会, 基盤研究(B), 北海道大学, 24K02389 - An Integrated Approach for Uncertainty Reduction of DIR-based Dose Accumulation in Adaptive Radiotherapy
Grants-in-Aid for Scientific Research
01 Apr. 2024 - 31 Mar. 2027
小橋 啓司, 橋本 孝之, 吉村 高明, 西岡 健太郎
Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 24K10878 - 肺癌に対する陽子線治療の選択基準確立に向けた心肺相互作用勘案NTCPモデル構築
科学研究費助成事業
01 Apr. 2022 - 31 Mar. 2025
青山 英史, 鈴木 隆介, 宮本 直樹, 高尾 聖心, 金平 孝博, 橋本 孝之, 小橋 啓司, 西岡 健太郎, 田口 大志
日本学術振興会, 基盤研究(B), 北海道大学, 22H03008 - AIを活用した小児がん陽子線照射のトリプルハイブリッド遠隔治療計画システムの開発
科学研究費助成事業
01 Apr. 2022 - 31 Mar. 2025
橋本 孝之, 高尾 聖心, 小橋 啓司, 吉村 高明, 西岡 健太郎
日本学術振興会, 基盤研究(C), 北海道大学, 22K07631 - 超高線量率陽子線治療に適したリアルタイム飛程検出法の開発
科学研究費助成事業
09 Jul. 2021 - 31 Mar. 2024
松浦 妙子, 田中 創大, 富岡 智, 橋本 孝之, 栗山 靖敏
FLASH放射線治療は，通常の放射線治療の線量率の数百倍から数千倍高い線量率（40 Gy/s程度以上）を用いる超高線量率照射法である。抗腫瘍効果を変えずに正常組織の障害発生を顕著に抑制できることが知られており，これまでの治療様式を大きく変えるインパクトがある．本研究では，数年以内に臨床利用が期待される超高線量率陽子線治療に適用する心電図検査式リアルタイム飛程検出法の実用化に向けた基盤技術開発を行うことを目標とした研究開発を行っている．本年度はまず，シミュレーション検討に用いるためにCT及び超音波の両方のイメージングに対応した人体ファントムを選定し（Model 057A，CIRS社製），音波伝搬シミュレーションの構築を開始した．まず人体ファントムを陽子線治療計画用のCT装置で撮影し，各ボクセルのCT値に対して陽子線治療に用いられているCT-相対阻止能テーブルを用いて水密度を割り当て，モンテカルロシミュレーションによって陽子線線量分布を計算した．一方で，音波発生・伝搬シミュレーションの準備として，文献を参照しながら各ボクセルに対してCT値に応じた音響特性（音速や音響インピーダンス，グルネイセン係数など）を割り当てた．人体ファントムに対して，FLASH線量率で陽子線を照射し，これを音源とした音波伝搬をシミュレーションした．音波は体表面に配置した複数のセンサーで受信する設定とした．本年度はまた，次年度予定している陽子線照射実験に用いる予定の寒天をベースとしたファントムの構造と形状の検討を行い，試作を行った．
日本学術振興会, 挑戦的研究(萌芽), 北海道大学, 21K19434 - Research and development about helium and proton hybrid system with proton CT and Immuno-radiotherapy
Grants-in-Aid for Scientific Research
01 Apr. 2019 - 31 Mar. 2024
白土 博樹, 宮本 直樹, 高尾 聖心, 茶本 健司, 橋本 孝之, Nam JinMin, 西岡 健太郎, 小野寺 康仁, 松浦 妙子, 梅垣 菊男, 平田 雄一, 田中 創大, 清水 伸一
① 2019年度に決定した、短時間（0.1秒以下）でエネルギー変更可能な小型加速器の基本設計に基づき、小型加速器の要素技術の設計を行い、短時間（0.1秒以下）でエネルギー変更を可能とする回転ガントリーを含む照射・輸送系の磁場制御設計を行った。
② 陽子からヘリウムに短時間で加速粒子を変更できる混合加速方式を検討、2023年度に制作開始するべく、陽子線CTの機器としての仕様を検討した。
③ 陽子線CT値-ヘリウムSPR変換プロセスと、X線CT値利用時の精度を比較し、高エネルギー陽子線CTに必要な要素機器と制御方式の仕様を明確化した。
④ 高エネルギー陽子線ビームを照射する場合に、ビームの人体への入射方向を意図的に偏心させ、ノズルの外側から照射野中心に向かったビームアングルとするための加速器・照射系の検討を行った。
⑤ PD-1阻害剤およびPD-L1阻害剤を用いて、がん細胞の制御に最適なLET、ROSとミトコンドリアの分布を計測し、放射線と阻害剤の組み合わせによる相関を検討した。T細胞のPD-1阻害に関する条件検討を行っていたところ、当初の想定に反し、がん細胞での観察と類似の条件ではT細胞の観察が困難であることが判明した。T細胞を観察した上で条件決定することが不可欠であるため、T細胞のPD-1阻害に関する条件決定のための追加検討事項として、培養条件や使用する蛍光色素の種類を複数追加し、T細胞を観察するための至適条件の検討を行った。
Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (B), Hokkaido University, 19H03591 - Challenge to elucidate and optimize the radiation sensitizing effect of gold nanoparticles by quantum life science approach
Grants-in-Aid for Scientific Research
01 Apr. 2018 - 31 Mar. 2022
Hashimoto Takayuki
Radiation effects on metals, such as gold nanoparticles, was investigated to improve the results of radiotherapy for intractable cancers. Observation of gold particles in cellular microstructure was delayed due to damage to an ultra-high voltage electron microscope caused by the great earthquake, and proton irradiation experiments using gold nanoparticles that can be administered into the body were not conducted during the period due to the intermittent issuance of a state of emergency declaration and priority measures to prevent spread of the COVID-19. In relation to the interaction between metals in the body and radiation, we published papers on proton therapy for pediatric cancer, in which the radiosensitizing effect of gold particles is expected to be clinically applicable, and on a comparative study of the effects of proton beams and carbon ion beams on implantable medical devices such as pacemakers, respectively.
Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 18K07660 - Development of minimum invasive real-time markerless image guided radiotherapy technique using minimum space information.
Grants-in-Aid for Scientific Research
01 Apr. 2018 - 31 Mar. 2021
Shimizu Shinichi
In the real-time tumor tracking radiotherapy, feature point information, that is used for gating, is obtained by fluoroscopic X-ray images. There still problems exist:1.X-ray exposure from diagnostic X ray that used for gating 2.insertion of a gold marker etc. as a feature pointReduce or eliminate X-ray exposure by making the observing area through diagnostic X-rays as small as possible to acquire target movement information or establishing the method of processing gating information obtained using MRI technology without using fluoroscopy were considered to be the goal of this study.
X-rays are still optimal for acquiring organ motion information within human body necessary for gating treatment in real time, but a method for limiting the range was achieved in this study. In addition, we succeeded in trying to visualize the position of organs with MRI image data without using X-rays when preparing for treatment, and there were expectations for the promotion of future research.
Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (B), Hokkaido University, 18H02758 - Development of a real-time tumor-tracking proton beam therapy with molecular imaging for intractable cancers using gold nanoparticles preparation
Grants-in-Aid for Scientific Research
01 Apr. 2014 - 31 Mar. 2017
Hashimoto Takayuki, HASHIMOTO Shintaro, Kwon Jihun, Sutherland Kenneth L
We conducted basic researches for developing a novel proton beam therapy as one of the multimodal therapies to improve treatment results of intractable cancers using gold nanoparticles (GNPs) as a radiosensitizer. The spatial dose distributions and dose enhancement ratio around the proton beam axis in the presence and absence of a GNPs were calculated using the Geant4 Monte Carlo simulation toolkit under various conditions. GNPs form clusters when taken up by tumor cells and shield a part of secondary electrons. Our results suggest the improvement of treatment accuracy in clinical use, because the dose enhancement is overestimated without considering energy absorption by the clustered GNPs. It is necessary to evaluate the sufficient safety including animal test before clinical application of GNPs preparation, which is highly concentrated enough to distinguish the difference of CT value as the tumor imaging agent or the fiducial marker.
Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 26461876 - Novel approaches to cancer treatment based on DNA damage and tumor immunity activation induced by proton beam irradiation
Grants-in-Aid for Scientific Research
01 Apr. 2012 - 31 Mar. 2015
TSUBOI Koji, SAKAE Takeji, KUMADA Hiroaki, MORITAKE Takashi, HASHIMOTO Takayuki, SUZUKI Kenshi, ITO Atsuo, OHNO Tadao
1) The “complex DNA damages” induced by irradiation make a significant impact on cell inactivation or transformation. Although complex DNA damage formation was dependent on radiation quality in the early phase after irradiation, senescence-like growth arrest was suggested to be the major cellular response in the later phase, regardless of radiation quality.
2) A selective Cox-2 inhibitor “celecoxib” sensitized malignant brain tumor cells to gamma-rays by loading ER stress. The major modality of cell death induced was autophagy, suggesting that celecoxib is a promising candidate for radosensitizing refractory malignant brain tumors.
3) Local cancer radiotherapy may have an effect as an immune adjuvant. We found that a tumor-specific immune system was activated when the primary tumor was cured by irradiation. This “abscopal effect” was effective even in the brain. In contrast, primary tumor recurrence after irradiation resulted in suppression of tumor immunity.
Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (B), University of Tsukuba, 24390287 - Basic research for particle therapy using high enrgy proton in next generation
Grants-in-Aid for Scientific Research
01 Apr. 2012 - 31 Mar. 2015
SAKURAI Hideyuki, MATSUMOTO Hideki, ISHIKAWA Hitoshi, OKUMURA Toshiyuki, MORITAKE Takashi, HASHIMOTO Takayuki, MIZUMOTO Masashi, MATSUMOTO Yoshitaka
There is high possibility to increase cure rate of cancer by using new radiation therapy, proton beam therapy and boron neutron capture therapy (BNCT). We performed not only basic research of these two particle therapy, but also clinical studies of chemoproton therapy for esophageal cancer, locally advanced lung cancer, and cholangiocarcinoma. As a result, chemoproton therapy, which was new field of cancer therapy, showed high treatment effect with less toxicity for the heart and lung. We also carried out clinical study of proton for pediatric cancer, and started long term to follow up of 150 patients. For clinical study of BNCT, the treatments were finalized in 4 patients.
Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (B), University of Tsukuba, 24390286 - A translational research for promotion of multimodality therapy combined with proton beam therapy
Grants-in-Aid for Scientific Research
2009 - 2011
SAKURAI Hideyuki, MATSUMOTO Hideki, OHNO Tatsuya, MORITAKE Takashi, MIZUMOTO Masashi, OKUMURA Toshiyuki, HASHIMOTO Takayuki
The aim of this study is to promote translational research for multimodality therapy combined with proton beam therapy (PBT). We found increasing radiobiological effect on late phase of bragg peak, and also detected apoptosis in the crypt cells irradiated with very low dose of proton. For normal tissue reaction, dose-volume relationship was clearly found both in rib fracture on PBT for liver cancer and in pneumonistis on PBT combined with chemotherapy for advanced lung cancer. Finally, from these translational researches, we have started clinical trials for advanced lung cancer and pediatric cancer as a multimodality therapy combined with PBT.
Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (B), University of Tsukuba, 21390338
